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There are significant differences in the pharmacokinetics, pharmacodynamics, brain 
structure, neurochemistry and sex hormones of males and females, yet females are precluded 
from preclinical studies, with conclusions drawn from male only results and applied to 
females. Thus, females are still treated with the same dose of many drugs, including 
antipsychotics, as males. To investigate whether any sex differences were evident in the 
responses exhibited by male and female rats after acute exposure to the commonly used 
atypical antipsychotic olanzapine, several behaviours were observed. These were anxiety, 
locomotor activity and spatial working memory, the effects of antipsychotics on which are 
controversial, and often unexplored in comparison to commonly researched extrapyramidal 
side effects. 80 PVG/c hooded rats were randomly assigned to one of four groups in which 
they were administered a low, medium or high dose of olanzapine, or vehicle for control 
animals at post-natal day (PND) 70 for 42 days. Immediately after 21 days of treatment at 
PND91, and after 42 days at PND112, subjects were tested in the zero maze, light-dark box, 
open field and the Y-maze. It can be concluded that there are marked differences in the 
behavioural responses to olanzapine in males and females, eliciting a clear anxiogenic effect 
for females in several measures, especially at higher doses with regard to males. There is 
strong evidence to suggest that olanzapine has an anxiogenic effect on anxiety-related 
behaviours, however anxiolytic effects are still apparent. Nevertheless, it is clear that it does 
have an effect on anxiety-related behaviour. Olanzapine also has an overall negative effect on 
locomotor activity over time, though this effect is dose dependent. With regard to spatial 
working memory, there are also considerably contradictory findings, with the suggestion of a 
negative effect of olanzapine on memory over time, however it appears that females may be 
more resilient to this effect than males. Overall, it can be concluded that the response of 
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males and females to olanzapine differs in many cases. These results may have implications 
for the use of the drug with humans as it has been proven that females do experience 






There is substantial evidence to suggest that there are significant differences in the 
pharmacokinetics, pharmacodynamics, brain structure, neurochemistry and sex hormones of 
males and females. Despite this, females are treated with the same dose of antipsychotics as 
males. This is largely due to the fact that females are precluded from preclinical studies, with 
conclusions regarding the drug in question drawn from male only results applied to females, 
regardless of their differences. As a result, females have a higher risk for adverse effects and 
are likely to report an overall ineffectiveness of the drug. A better representation of females is 
essential to improve the safety and efficacy of various drugs, and therefore it is crucial that 
preclinical studies of drug effects include females, and that data is analysed by sex. 
Observing sex differences in behaviours such as anxiety, locomotor activity and spatial 
working memory are important as the impact of atypical antipsychotics for these behaviours 
is controversial. A thorough understanding of this impact will give researchers a clearer 
understanding of these effects, while controlling for sex-specific differences.   
 
1.2 Differences between males and females  
Sex is the classification of male or female based on genetic composition and 
reproductive organs and functions, while gender is a social construct, generally culturally 
determined, and is expressed in terms of masculinity, femininity, and the quality by which 
people identify themselves and how they believe others to behave (Soldin & Mattison, 2009; 
Soldin et al., 2011).  
Sex differences in the responsiveness of both rats and mice to a number of 
behaviourally active drugs have been regularly reported for nearly 50 years. However, a large 
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number of researchers who use rodents use only males in their drug studies (Hughes, 2007). 
The Food and Drug Administration (FDA) have suggested that women are subject to more 
adverse drug effects than men, and the effects are more severe (Soldin & Mattison, 2009). 
Multiple studies suggest that women also have a 50-75% higher risk for adverse drug effects 
than men (Haack et al., 2009). Between January 1997 and December 2000, 10 drugs were 
withdrawn from the market; eight of the 10 were withdrawn due to evidence of greater risks 
to women (US General Accounting Office, 2001). With regard to antipsychotic medication, 
several studies have addressed the issue of potential sex differences on both behaviour and 
tolerability of the drugs, yet no studies have actively investigated this difference specifically 
on behaviour, with most examining physiological differences such as weight gain or 
metabolic parameters (e.g. Davey et al., 2012). 
Various factors influence both circulating drug concentrations and concentrations at 
the site of action, and this determines the outcome of the drug (Hardman et al., 2001). 
Specifically, sex can influence how the body deals with a drug, as well as what the drug does 
to the body.  
Men and women differ in response to drug treatment as a consequence of many 
factors, including sex-specific differences in pharmacokinetics and pharmacodynamics, and 
sex specific differences in parameters such as body weight, height, body surface area, total 
body water, and the amount of intracellular and extracellular water (Anderson, 2008; Soldin 
et al., 2011). On average, women have a lower drug clearance and/or a smaller volume of 
distribution, as they are generally smaller in size and have a different body composition 
compared to men. Therefore, the recommended dose of a drug may result in higher drug 
concentrations for women (Chen et al., 2000). Pharmacodynamic factors may also increase 
female sensitivity to a given drug. For example, concentrations of a given dose of a drug 
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would be similar in both men and women, however, the drug-related response is often greater 
in females compared to males (Coker, 2008).  
In order for a drug to work, a minimum concentration at the site on which the drug 
exerts its action must be reached. This concentration must then be maintained within a given 
target range to allow for therapeutic efficacy (Soldin & Mattison, 2009). The quantity of the 
drug required to be effective is not far removed from the quantity that causes significant 
adverse effects. Therefore, maintaining this steady state is not as simple as administering one 
single dose of the medication. Many factors can affect the level of circulating drug 
concentrations, and it is becoming increasingly clear that men and women differ in their 
responses to drug treatment. For example, a man has an average body weight of 78 kilograms 
and 42 litres of total body water, while a woman has an average body weight of 68 kilograms 
and total body water of 29 litres (Soldin & Mattison, 2009).  Drug effects on behaviour in 
women compared with men is still largely unknown. Therefore, it is essential that sex-related 
differences in drug pharmacokinetics and pharmacodynamics must be assessed. An 




1.2.1.1 Absorption and bioavailability 
Drug absorption and bioavailability are influenced by drug- and route-specific factors, 
such as oral, intramuscular, intravenous or intraperitoneal administration (Soldin et al., 2011). 
Since oral drug administration is common in pharmacotherapy, it is important to consider the 
possibility that several physiological parameters can have a major impact on the rate of drug 
absorption. These include food interactions (e.g. grapefruit juice for certain drugs such as oral 
contraceptives), other impacts of oral contraceptives, lipid solubility and biliary secretion. 
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Gastric and hepatic enzymes and transport proteins that oral drugs interact with before 
reaching systematic circulation are critical parts of bioavailability (Giacomini et al., 2010; 
Kadono et al., 2010). These enzymes change across the course of development, forming the 
foundation for differences between males and females (Kennedy, 2008). These processes, 
both metabolic and transport, are crucial in determining the success or failure of drugs that 
are developed for oral administration. When successful, oral drugs are permeable, soluble and 
ineffectively metabolised by hepatic or intestinal enzymes. For example, the differences in 
the volume of distribution between males and females, alongside gastric alcohol 
dehydrogenase activity, can provide one reason as to why the bioavailability of alcohol is 
greater in females than it is in males (Parlesak, 2002). Transporter proteins also play an 
important role in the transportation of drugs into and out of cells, and are therefore involved 
in hepatobiliary and urinary excretion (Giacomini et al., 2010). Tissue distribution and 
elimination pathways, and consequently the efficacy and toxicity of drugs, can often be 
explained by transporter proteins.  
Women generally have a smaller body surface area, and gastric fluid flow, gastric 
emptying, gut motility and cardiac output are all slower in women compared to men (Soldin 
& Mattison, 2009; Smith, 2010). As a consequence, women have slower passage into the 
small intestine, which is the main site of drug absorption; therefore women will have a 
slowed absorption rate compared to men. If male data are used when making generalisations 
to females, this may result in lower peak levels of drug than expected for women (Bennik et 
al., 1998; Lorena et al., 2004). Gastric acid levels are also generally lower in women than in 
men, and duration of gastric acid secretion and gastrointestinal blood flow are commonly 
longer for women (Beierle et al., 1999). Absorption is mainly affected by the speed of gastric 
emptying and the presence of other substances which change the gastric pH, for example, 
proton pump inhibitors. Depending on drug ionisation this may result in an altered absorption 
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of acids and alkali, by slowing down the absorption of acidic compounds or speeding up the 
absorption of alkaline compounds (Ghandi et al., 2004; Smith, 2010). Gut transit times, the 
time it takes to digest a compound, also differ significantly between men and women, mean 




The distribution of a drug throughout the body is affected by multiple body 
composition factors. These differ between males and females. Sex differences in these 
parameters may account for differences in drug concentration at the target site and result in 
varying responses to the drug (Soldin & Mattison, 2009). Men have approximately 15% less 
body fat than women, and have more lean muscle mass (Smith, 2010). Total body water, 
extracellular and intracellular water, total blood volume, plasma volume and red blood cell 
volume are, on average, greater in men than women. This means that, for women, there is 
less volume available for a drug to be distributed (Smith, 2010; Soldin & Mattison, 2009). If 
the same dose of a water soluble drug is administered to a man and a woman, the volume of 
distribution will be increased in the man, thus decreasing drug concentration with respect to a 
woman (Soldin & Mattison, 2009).  
Conversely, if both a man and a woman were exposed to the same dose of a lipid-
soluble drug, a drug that readily enters body fat, the same parameters would mean an increase 
in the volume of distribution of the drug in females. This is due to increased body fat as a 
percentage of total body weight in women compared to men, which may increase the total 
amount of lipid-soluble, slowly metabolised drugs present in their body. Differences in body 
fat and organ blood flow for women have been implicated in a faster onset of action and 
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prolonged half-life, demonstrating a larger volume of distribution for lipid-soluble drugs 
compared to men (Houghton et al., 1992; Xue et al., 1997).  
Antipsychotic medications are lipophilic. For women, this means that there will be a 
greater distribution of the antipsychotic drug throughout their body for the same dose of the 
drug compared to men. When fat-soluble compounds such as depot medications are 
administered over time, more depot will accumulate in women, and this may mean that in 
order to reduce the risk of side effects, women need a longer interval between depot doses 
than men (Smith, 2010). 
 
1.2.1.3 Metabolism 
The main enzymes involved in hepatic drug metabolism belong to the Cytochrome 
P450 (CYP) group. Sex-related differences in pharmacokinetics may emerge from 
discrepancies in the regulation of CYP enzyme expression and activity, and this may be 
related to endogenous hormonal influences (Soldin & Mattison, 2009).  CYP1A2, 2C19, 2D6 
and 3A4 are the most important hepatic enzymes for the metabolism of antipsychotic and 
antidepressant drugs (Prior & Baker, 2003). Differences between men and women have been 
reported for all of these enzymes, illustrating sex difference in hepatic drug metabolism 
(Thurmann & Hompesch, 1998; Beierle et al., 1999; Tamminga et al., 1999; Hagg et al., 
2001; Meibohm et al., 2002; Parkinson et al., 2004). Higher activity in females of CYP3A4 
and 2D6 have been shown in studies of sex-based differences in CYP activity, and lower 
activity has been shown for CYP1A2, 2C19, and 2E1 compared to males (Hagg et al., 2001; 
Meibohm et al., 2002; Parkinson et al., 2004). It has been established that, compared to those 
of males, women displayed a 20-30% increased clearance for drugs that were CYP3A 
substrates on average (Greenblatt & von Moltke, 2008). Higher plasma concentrations of 
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clozapine and olanzapine have been found in females, and this appears to be caused by lower 
CYP1A2 activity (Lane et al., 1990; Kelly et al., 1999; Gex-Fabry et al., 2005).  
P-glycoprotein, a drug transporter protein, also appears to be implicated in drug 
metabolism. Men have more than twice as much of this protein compared to women, 
resulting in lower drug levels in the serum of women as more drug substrate is bound to this 
protein carrier (Meibohm et al., 2002; Fleeman et al., 2010).  
Olanzapine and clozapine are metabolised by CYP1A enzymes, which has higher 
activity for males (Cooper at al., 1984). This means that there is a prolonged half-life and 
reduced elimination rate in females. Olanzapine also demonstrates significantly higher 
plasma levels for women due to higher activity of CYP3A4 and CYP2D6 in women (Soldin 
et al., 2011).  
Due to increased body fat as a percentage of total body weight in women compared to 
men, women have larger lipid compartments, which leads to longer half-lives and therefore 
may result in the accumulation of lipophilic drugs, including antipsychotics. This suggests the 
need for longer dosing intervals, particularly during pregnancy (Pollock, 1997; Seeman, 
2004). The menstrual cycle, pregnancy and menopause are three physiological states that 
exist for women that do not occur in men. These states may affect drug metabolism in 
women, and therefore medication may need to be altered during these phases (Smith, 2010).  
 
1.2.1.4 Elimination 
The kidney is the main organ for drug elimination. There are known sex differences in 
all three of the major renal functions, including glomerular filtration, tubular secretion, and 
tubular reabsorption. In men, renal clearance is generally higher than in women (Gaudry et 
al., 1993; Berg, 2006). Alterations in renal blood flow, glomerular filtration rate, hepatic 
blood flow, bile flow and pulmonary function have been found to change the excretion of a 
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drug during pregnancy. For example, maternal renal plasma flow increases from 500 to 
700ml/min/1.73m
2
, 1.44 times greater than a non-pregnant woman, and 1.1 times greater than 
a male (DeCherney et al., 2006). A 10% lower glomerular filtration rate in women (Gross et 
al., 1992) results in 40-50% higher plasma levels while treated with the SGA amisulpride 
(Muller et al., 2006). These factors may result in drug accumulation within the body, and 
therefore a significantly decreased renal clearance of antipsychotic drugs in women. For 
example, when matched for weight, a man will clear the drug faster and have lower plasma 
levels than a woman. It has been found that men clear olanzapine 38% faster than women, 
and therefore women are at an increased risk of adverse side effects because the drug stays in 
the body for longer (Smith, 2010). Consequently, women require less antipsychotic 
medication than men.  
 
1.2.2 Pharmacodynamics 
There appear to be significant sex differences with regard to cortisol. Women are 
more sensitive to cortisol suppression, and therefore they may also be more sensitive to the 
effects on basophils, a type of white blood cell that helps prevent blood from clotting too 
quickly and promote blood flow to tissues, and helper T lymphocytes, or cells that are 
involved in adaptive immune responses (Leblhuber et al., 1993; Tanaka et al., 1993; 
Vierhapper et al., 1998). 
 
1.2.3 Sex-specific conditions affecting pharmacokinetics and pharmacodynamics  
The influence of sex hormones and changes in sex hormone levels can impact the 
pharmacokinetics of a drug on physiological functions. Metabolic changes in women may be 
dependent on hormone levels such as increased levels or estrogen or progesterone, which can 
alter hepatic enzyme activity and therefore increase drug accumulation or decrease drug 
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elimination. These hormone levels fluctuate during the menstrual cycle, while using oral 
contraceptives, and during pregnancy or menopause (Soldin & Mattison, 2009).  Throughout 
the menstrual cycle, sex hormone levels are associated with specific hepatic enzyme 
activation and the elimination rate of certain drugs. For example, during the follicular phase, 
caffeine elimination is higher, and is prolonged during mid-luteal phase (Buchanan et al., 
2009).  
Numerous physiological changes occur during pregnancy that have been shown to 
affect drug plasma concentrations. Volume of distribution can be affected by increased 
plasma volume, increases in extracellular and intracellular fluid and body water; 
cardiovascular plasma concentrations can be affected by plasma volume expansion, increase 
in cardiac output and regional blood flow changes, and decreases in binding proteins, 
prolongation of gastric evacuation time, liver CYP enzyme changes, and increased renal 
blood flow and glomerular filtration rate affect drug plasma concentrations (Mattison et al., 
1991; Loebstein et al., 1997).  
Gastric acid secretion and gastric motility alterations and a decreased rate of drug 
metabolism and renal elimination have been demonstrated for women. These factors are 
associated with changes in reproductive hormone levels during the menstrual cycle (Hutson 
et al., 1989; Kashuba & Nafziger, 1998). Due to these factors, drug levels in women may 
remain higher resulting in prolonged clinical and adverse effects. Therefore, it is worth 
considering that women may require a lower dose compared with men (Stahl, 1998).  
 
1.2.4 Brain organisation and neurochemistry 
There are several fundamental differences between males and females that are firmly 
established in biology. Although male and female brains are very similar, there are consistent 
differences that have critical implications for each sex. Brain sex differences uniquely affect 
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biochemical processes, may contribute to the susceptibility to specific diseases, and may 
influence specific behaviours (Ngun et al., 2011). In turn, these differences may impact how 
males and females tolerate specific drugs, and how drugs work within their brains.  
Organisation of brain areas such as the preoptic area (Gorski et al., 1978), neocortex, 
hippocampus and the corpus callosum (Juraska, 1991) appears to differ between male and 
female rats, as does the organisation of the amygdala (Mizukami et al., 1983; Hines et al., 
1992), and the activity of several neurotransmitters including serotonin (Carlsson & Carlsson, 
1988; Zhang et al., 1999), and striatum and nucleus accumbens dopamine (Becker, 1999).  
Sex differences are also demonstrated by two targets for selective serotonin reuptake 
inhibitors (SSRIs), the 5-HT1A receptor and 5-HTT transporter. SSRIs are psychotropic drugs 
that are used to treat depressive, anxiety, and personality disorders.  Throughout the cortical 
and subcortical brain regions, women have significantly higher 5-HT1A receptor and lower 5-
HTT binding potentials. They also display a positive correlation between 5-HT1A receptor 
and 5-HTT binding potentials in the hippocampus (Jovanovic et al., 2008). These distinct 
binding potentials may therefore result in biological differences in the serotonin system, and 
consequently sex differences in psychiatric disorder prevalence, especially for depression and 
anxiety. Some atypical antipsychotics, such as aripiprazole, are partial 5-HT1A agonists, 
which means that they bind to and activated the 5-HT1A receptor, facilitating its action (Stark 
et al., 2007). 5-HT1A receptor activation has been linked to increased dopamine release in the 
medial prefrontal cortex, striatum and hippocampus, areas in which increased levels of 
dopamine is useful in the treatment of schizophrenia (Li et al., 2004; Bantick et al., 2005).  
Several neuroanatomical sex differences have been observed in the rat brain, 
including differences in synaptic patterns and neuronal density and the posterodorsal aspect 
of the medial amygdala is 85% larger in male rats (Hines et al., 1992).  Similarly for humans, 
females have over 20% fewer dopaminergic neurons in the substantia nigra pars compacta 
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compared to men (Dewing et al., 2006). The substantia nigra is made up almost entirely of 
dopaminergic neurons and is involved in the control of motor activity (Groenewegen, 2003). 
In the amygdala, adult males have a larger medial nucleus compared to adult females 
(Mizukami et al., 1998). 
With regard to neurochemistry, males and females demonstrate different patterns of 
transmitting, regulating, and processing biomolecules (Ngun et al., 2011). In an animal study, 
male rats have more norepinephrine (NE) in the amygdala and hypothalamus 25 days after 
birth, but the direction of this sex difference is reversed at day 300 (Siddiqui & Shah, 1997). 
Dopamine activity is upregulated only in male rats, and NE activity is increased only in 
females in response to chronic stress (Luine, 2002). In a study by Ingalhalikar et al. (2014), 
males had greater intra-hemispheric connectivity compared to females, who showed greater 
inter-hemispheric connectivity.  
 
1.3 Importance of female models  
Given this information illustrating the size of the difference between males and 
females in terms of drug pharmacokinetics and pharmacodynamics, there are still strikingly 
few attempts to resolve this through the inclusion of women in preclinical and clinical 
studies; many researchers continue to ignore females in their animal studies and study males 
exclusively (Hughes, 2007). This is alongside the fact that women are still underrepresented 
in preclinical and clinical trials, and there is an absence of comparative studies exploring sex 
differences in the efficacy and adverse effect profile of SGAs (Aichhorn et al., 2006).  
Antipsychotic medication is developed and pre-clinically tested predominantly on 
young fit males, while young women of reproductive age have often been excluded from the 
drug development process. As a result, a large amount of the information available about 
antipsychotic effects and adverse effects is deduced from the effects of trials on young men. 
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It has been demonstrated that for some drugs there is more than a 40% difference in 
pharmacokinetics between women and men (Anderson, 2008); therefore it is probable that 
the biological differences between males and females do affect their response to antipsychotic 
medication. 
This has resulted in a lack of data to evaluate possible sex differences in drug efficacy 
and adverse effects (Aichhorn et al., 2005). This means that caregivers and health 
professionals are often left without knowledge of the appropriate dose or use of the drug in 
women, and therefore must estimate based on the limited amount of knowledge available. 
The principles of clinical pharmacology and the pharmacokinetics of a drug should be 
understood, as they apply to a given drug when determining what to prescribe.  
These sex differences in pharmacokinetic factors mean that for women, the effective 
dose of many psychotropic drugs is lower compared to that of men (Melkersson et al., 2001). 
In studies involving first-generation antipsychotics, it has been found that a dose must be one 
and a half to two times higher in men compared with women to achieve a similar clinical 
response (Arnold et al., 2004).  
Considering that behavioural pharmacological research with laboratory animals aims 
to produce ideas about the relationships between drugs and behaviour that may have research 
inferences for understanding the pharmacotherapy of human disorders that define both sexes, 
using male rodents only could be limiting, given the information that males and females 
differ considerably in their pharmacokinetic and physiological characteristics (Hughes, 
2007). For example, even though anxiety disorders are revealed to be more common amongst 
females than males (Blehar, 1995), most rodent studies investigating the effects of anxiolytic 
drugs have involved males only, even given that fear responses in animals are analogous to 
anxiety reactions in humans (Palanza, 2001). Therefore, it is likely that these studies which 
use male rodents only may not have the same degree of relevance to women as to men.  
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One reason why female rodents have been ignored is the widely held belief that their 
oestrous cycle may confound the effects of an experimental manipulation (Meziane et al., 
2007). Hormonal changes during the cycle do indeed affect how females may react to a drug; 
for example, amphetamine increases the locomotor stimulant effect during the oestrous cycle 
in female rats, suggesting potentiation of striatal dopamine release by oestrogen or 
progesterone (Becker & Cha, 1989). Male hormones, however, can also interact with drug 
effects. For example, testosterone was found to increase ethanol-related aggression in male 
mice (DeBold & Miczek, 1985). Furthermore, in order to successfully generalise results of 
drug effects on human females, investigating the specific changes in behaviour produced by 
hormonal influences is of considerable importance to establish an accurate representation of 
these effects.  
 
Given this information, it seems useful to include females in studies of drug effects, 
monitoring their oestrous cycle changes if the associated hormonal state is believed to be 
important. Male-only studies of drug effects may be irrelevant as the assumption that both 
males and females will demonstrate the exact same behaviour as that observed of males is not 
a reliable model of behaviour for females (Hughes, 2007). It appears that sex differences in 
animal models may be more relevant to the clinical setting than previously thought (Weston-
Green et al., 2011).  
The prevalence of psychiatric disorders also differs between males and females, and 
both men and women may present their symptoms differently. Specifically, schizophrenia 
research has showed that this disorder follows a different course in females compared to 
males, and this may have an impact on both the preferred treatment and the treatment 
outcome (Aichhorn et al., 2006).  
20 
 
It is important to look at more personalised medicine concepts instead of the ‘one-
drug-fits-all’ approach, especially given that more than 70% of schizophrenia patients treated 
with SGAs discontinue their medication within 18 months of treatment because of the side 
effects accompanying drug treatment (Lieberman et al., 2005). Current evidence is derived 
from small studies that had not originally been designed to assess sex differences. Therefore, 
further studies are needed, especially prospective trials on sex-related differences in specific 
drug side effects to confirm exploratory findings (Haack et al., 2009). Without these, it will 
be difficult to make generalisations to both male and female human populations based solely 
on male preclinical studies.  
The inclusion of women in preclinical (and clinical) trials and analysing data by sex 
instead of generalising male findings to females will provide more information on drug dose, 
pharmacokinetics and pharmacodynamics, and therefore advance the understanding of drug 
efficacy and safety in women (Aichhorn et al., 2006).  
 
1.4 Olanzapine 
Second generation (or ‘atypical’) antipsychotics (SGAs) are the mainstay treatment 
for schizophrenia and bipolar disorder (De Oliveira & Juruena, 2006). They are a varied class 
of drugs, including olanzapine, clozapine, risperidone, and quetiapine, which are grouped 
together based on their lower risk for extrapyramidal symptoms (EPS), which are typically 
associated with their first-generation counterparts (De Oliveira & Juruena, 2006). A common 
characteristic of SGAs is prominent serotonin 5-HT2A antagonism combined with dopamine 
D2 antagonism, as the positive symptoms of schizophrenia are believed to arise from 
hyperdopaminergic activity (Karl et al., 2006). SGAs also have a unique receptor-binding 
profile for histamine, muscarinic, adenosine and serotonin receptors, the consequence of 
which can result in a combination of both distinctive and overlapping side effect profiles (Hill 
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et al., 2010). SGAs therefore have superior therapeutic efficacy in treating not only the 
positive symptoms of schizophrenia, which was the main target of conventional 
antipsychotics, but also the negative and cognitive symptoms (Conley & Mahmoud, 2001).  
Alongside risperidone, olanzapine is one of the two most commonly prescribed 
atypical antipsychotics in New Zealand (Wheeler, 2006; Gee & Croucher, 2011; Monasterio 
& McKean, 2011). It is the most commonly prescribed atypical antipsychotic for treating 
bipolar disorder, and is often prescribed off-label for treating refractory depression and 
borderline personality disorder (Monasterio & McKean, 2011). In a recent study by Dey et al. 
in 2016, olanzapine had the highest prescription rate of 31% of 451 patients in New Zealand 
when compared to other second generation antipsychotics and conventional antipsychotics, 
including risperidone, quetiapine and haloperidol. In the United States and the United 
Kingdom in 2006, both olanzapine and risperidone were prescribed equally often, and 
olanzapine accounted for 65% of atypical antipsychotic prescriptions in Australia (Wheeler, 
2006).  
Olanzapine has been available in New Zealand since 1997 and is a second-generation 
antipsychotic, antimanic and mood stabilising medication that demonstrates a broad 
pharmacological profile across a number of receptor systems (MedSafe, 2017). Olanzapine 
has demonstrated a range of receptor affinities for serotonin (5-HT), dopamine (DA), 
cholinergic muscarinic receptors, 1 adrenergic and histamine receptors. Consistent with the 
receptor binding profile, it is a 5-HT, DA and cholinergic antagonist. Olanzapine selectively 
reduces the firing of mesolimbic dopaminergic neurons, while having little effect on the 
striatal pathways which are involved in motor function. As a result, olanzapine has a lower 
risk for EPS. This medication reduced a conditioned avoidance response (a test indicative of 
antipsychotic activity) at doses below those producing catalepsy (Medsafe, 2017). Olanzapine 
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has also been shown to increase responding in an anxiolytic test (MedSafe, 2017). It has been 
shown to significantly reduce negative as well as positive symptoms of schizophrenia.  
Olanzapine reaches peak plasma concentrations after oral administration and 
absorption within 5 to 8 hours (MedSafe, 2017). It is metabolised by the liver by cytochromes 
P450-CYP1A2 and CYP2D6, where the main circulating metabolite is the 10-N-glucuronide 
which cannot pass the blood-brain barrier. The mean half-life of olanzapine is 33 hours, and 
mean plasma clearance is 26L/hr. Smoking status, age, and sex can vary the 
pharmacokinetics; for example, the mean half-life was prolonged in female subjects 
compared to males (36.7hr vs. 32.3hr) and clearance was reduced (18.9L/hr vs. 27.3L/hr) 
(MedSafe, 2017). 
It is apparent that sex differences with regard to efficacy and adverse effects of SGAs 
have not been well studied to date, but it is clear that there are some disparities between 
males and females, and some physiological effects such as weight gain, hyperprolactinaemia 
and cardiac effects are particularly problematic for women (Aichhorn et al., 2007). 
Olanzapine appears to be associated with greater bodyweight gain than other SGAs, and 
serious side effects such as metabolic syndrome are more frequent in females, highlighting 
the need for further research.  
Plasma levels are significantly higher in women because of increased CYP1A2 and 
CYP2D6 metabolism, and lower CYP1A2 enzyme activity. Therefore, dose-related plasma 
concentrations of olanzapine are significantly higher in women compared to men (Weiss et 
al., 2005). Olanzapine clearance is also higher in men (Callaghan et al., 1999).  Strong drug-
specific metabolic changes have been associated with olanzapine and quetiapine (Haack et 





Several examples of behaviour that have been shown to produce sex differences in 
drug studies include motor activity, fear, and spatial learning (Hughes, 2007).  
Numerous animal models are available for the study of various drugs, including 
SGAs. However, most behavioural studies focus only on EPS (E.g. Glenthoj et al., 1990; 
Drago et al., 1997) without looking at other behaviours such as anxiety, memory, fear, or 
general motor activity. Therefore, it would be difficult to cross correlate these behavioural 
findings (Karl et al., 2006). The effects of antipsychotic treatment on memory (Green et al., 
1997; Wolff & Leander, 2003) and anxiety (Russell et al., 1987; Simon et al., 1993; Rodgers 
et al., 1994; Blin et al., 1996; Ishida-Tokuda et al., 1996; Singh et al., 1997; Nowakowska et 
al., 1999) are disputed in terms of whether there is a positive or negative effect, or no effect.  
 
1.5.1 Anxiety 
In a study by Karl et al. (2006), it was found that treatment with SGAs resulted in 
diminished motor activity and exploration, impaired working memory and increased anxiety 
levels. When comparing rats treated with SGAs to conventional antipsychotics and placebo, it 
was found those treated with SGAs showed more anxiety-like behaviours than controls, but 
fewer than rats treated with conventional antipsychotics (Hillert et al., 1992; Marder et al., 
1997; Muller et al., 2010).  
Many SGAs are often prescribed for treating anxiety-related disorders such as 
obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) and panic 
disorder. Clozapine, olanzapine, quetiapine and risperidone have all been shown to alleviate 
the symptoms of these disorders, but there are several studies that have reported they can 
worsen the symptoms of the same disorders (Sun et al., 2010). Preclinical evidence of the 
anxiolytic property of SGAs is inconclusive, where various studies have found anxiolytic-
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like, anxiogenic-like or no effect on anxiety-like measures (Karl et al., 2006; Sun et al., 
2010). However, Mead et al. (2008) and Sun et al. (2010) found that rats treated with 
olanzapine, clozapine or risperidone showed anxiolytic-like behaviours which were not 
attributable to their antipsychotic effect or effects on motor functions or learning and memory 
processes, suggesting that olanzapine and risperidone may possess an anxiolytic-like 
property.  
In spite of some negative evidence for the anxiolytic property of SGAs, there is a 
sufficiently large amount of evidence favouring olanzapine’s dose-dependent anxiolytic 
action. Therefore, examining the effect of olanzapine on behaviour can further assist in 
understanding the anxiolytic-like property of this drug.  
 
1.5.2 Locomotor activity 
Olanzapine has been shown to significantly reduce locomotor activity, which may be 
described as a sedative effect of the drug (Evers et al., 2010; van der Zwaal et al., 2010; 
Muller et al., 2010). Consistent findings have been found in rats (Hillebrand et al., 2005; 
Stefanidis et al., 2009) and humans (Callaghan et al., 1997; Putzhammer et al., 2005; Roerig 
et al., 2005).  
In a study by Davey et al. (2012), there was a reduction in locomotor activity, as 
observed in an open field test, in female rats treated with 2mg/kg olanzapine between 15 and 
20 minutes and between 20 and 25 minutes. However, the female rats treated with 4mg/kg 
olanzapine only showed decreased locomotor activity between 15 and 20 minutes. Male rats 
treated with both 2 and 4mg/kg olanzapine exhibited reduced locomotor activity between five 
and 10 minutes, and male rats treated with 2mg/kg also showed reduced movement between 
15 and 20 minutes and 20 and 25 minutes.  
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In a more recent study, rats treated with olanzapine showed reduced locomotor 
activity in terms of both total distance travelled and velocity throughout treatment periods of 
8, 16, and 36 days (Qingsheng et al., 2014) as measured in an open field test.  
Sedative side effects are common for antipsychotics (World Health Organisation 
[WHO], 1998), therefore a reduction in general motor activity is to be expected. However, 
the extent of this with relation to males and females is unclear. 
 
1.5.3 Spatial working memory 
There is a lack of information on the effects of SGAs on learning and memory in 
animal studies. One study by Skarsfeldt (1996) examined the effects of acute administration 
of several SGAs including olanzapine on learning of young adult rats in the water maze. It 
was found that quetiapine had no effect on spatial learning, clozapine impaired performance 
in the early trials but was ineffective during the later trials, and olanzapine and risperidone 
disrupted learning but not motor behaviour.  
Another study by Rosengarten and Quartermain (2002) found that, when investigating 
the effects of chronic administration of SGAs on spatial learning and memory, risperidone 
and clozapine significantly disrupted learning processes, while olanzapine had no effect.  
Terry et al. (2002) compared haloperidol with olanzapine for 45 and 90 days in a 
chronic study using the water maze task for effects on spatial learning and memory. After a 
4-day drug washout period, previous exposure to neither haloperidol nor olanzapine for 45 
days produced any significant effects on spatial learning in the water maze. However, after 90 
days, both haloperidol and olanzapine resulted in a clear impairment of spatial learning. This 
result was replicated by Muller et al. (2010). It was also found that radial arm maze 
performance was impaired in rats treated acutely with olanzapine, clozapine and scopolamine 
(Ortega-Alvaro et al., 2005). 
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Working memory and attention are generally impaired in patients with schizophrenia, 
and since DA agonists may facilitate working memory, DA antagonists, such as typical 
antipsychotics, may impair working memory (Ortega-Alvaro et al., 2005). The performance 
of rodents in spatial memory tasks that are used to assess particular components of cognition 
involved in schizophrenia also appears to be disrupted by olanzapine (Muller et al., 2010). 
Because SGAs have fewer D2 antagonistic properties compared to typical antipsychotics, 
they have been shown to improve working memory in schizophrenia.  
 
1.6 Rationale, aims and hypotheses 
As there is a relative lack of research investigating sex differences in the efficacy and 
safety of psychotropic drugs or studies including females in preclinical investigations of drug 
effects, the main aim of this study was to investigate whether any sex differences were evident 
in the behaviours exhibited by male and female rats after acute exposure to the commonly used 
atypical antipsychotic, olanzapine. Many studies analysing sex are purely reflective, and did not 
investigate distinctions between males and females. While there is evidence to suggest that 
males and females are remarkably different with regard to their pharmacokinetics, 
pharmacodynamics, brain structure and neurochemistry and sex hormones, in many instances, 
males and females are treated the same with regard to drug prescription for disease or disorder 
and drug dosage. In addition, females are shown to have higher risk for adverse effects than 
males (Soldin & Mattison, 2009; Haack et al., 2009).  
Furthermore, it has been well documented that there are clear sex differences in the 
effects of many drugs, e.g. alcohol and antihistamines (Soldin et al., 2011). So it is important 
to consider that sex differences in the effects of other psychotropic drugs are not improbable.  
Therefore, it was hypothesised that acute exposure to olanzapine would result in 
different behavioural responses between males and females, especially at higher doses. While 
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there is evidence of olanzapine-related effects on anxiety, locomotor activity and spatial 
working memory, none of the previously stated studies focused on sex differences in these 
behaviours or analysed their data by sex. In fact, most, if not all of these studies focused 
exclusively on one sex, with the majority using male rats only. Thus, while olanzapine-
related differences have been found with regard to these behaviours, it is difficult to conclude 
that the results apply to both sexes, or to generalise findings to entire human populations. 
Anxiety was chosen as there is much controversy over whether atypical antipsychotics are 
anxiolytic, anxiogenic, or have no effect on anxiety. This study therefore aimed to clarify this 
issue, while determining if any sex difference in the results may account for some of this 
controversy. Although locomotor activity and spatial working memory have been shown to 
be impaired with SGAs, a third aim of the current study was to determine to what extent any 




2.1  Subjects 
The subjects were a total of 40 male and 40 female PVG/c hooded rats, which were 
bred in the Animal Facility of the Department of Psychology, University of Canterbury. All 
rats were weaned at 28 days old, and were assigned to cages in groups of three or four 
individuals of the same sex. This arrangement ensured sex differences in responsiveness to 
OLA could be analysed. All rats had free access to food and water, and were housed in a 
room with a 12-hour light/dark cycle, with lights on at 0800h. At the beginning of treatment, 
equal numbers of each sex were 70 days old, when the rats are young adults, as this age, on 
average, is the age humans will experience their first schizophrenic episode.  
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The care and experimental treatment of the rats complied with Parts 5 (Codes of 
Welfare) and 6 (Use of Animals in Research, Testing, and Teaching) of the New Zealand 
Animal Welfare Act, 1999, and had been approved by the Animal Ethics Committee of the 
University of Canterbury.  
 
2.2  Drug and drug exposure 
The drug studied was the second generation antipsychotic olanzapine, administered 
via drinking water. From records of the rats’ bodyweights and daily water intake, it was 
calculated that, to achieve as near as possible the target doses of approximately 8, 12 and 
16mg/kg/day (referred to as low, medium and high) olanzapine, the drinking solutions should 
contain 50mg/litre, 75mg/litre and 100mg/litre respectively for males, and 40mg/litre, 
60mg/litre and 80mg/litre for females. This difference for the two sexes was to take account 
of the fact that, because female rats drink significantly more water/kg than males (due to their 
higher levels of circulating hormones associated with diuresis, McGivern et al., 1996), they 
need lower concentrations of olanzapine to achieve the same daily doses. The drug was 
dissolved in a 0.001M solution of acetic acid and diluted with tap water to administer the 
final dose. All animals were weighed every seven days and the drug was prepared and 
provided weekly, allowing drug intake over the previous week to be measured. Therefore, 
adjustments could be made to the solution depending on the amount of water consumed and 
the weight of the animals. In doing so, it was possible to ensure rats were receiving 
appropriate target doses.  
Equal numbers of males and females were randomly assigned to one of four groups: 
low (8mg/kg/day olanzapine), medium (12mg/kg/day), or high (16mg/kg/day) olanzapine, or 
0.1M acetic acid for control animals, to take account of any unanticipated effect of the 
vehicle. Final doses administered to experimental rats were approximate, and were as close as 
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possible to these target doses. Experimental rats were given free access to the drug or vehicle 
for 42 days. The target doses of olanzapine and the duration of treatment were based on its 
pharmacological and clinical profile, selected to closely represent the clinical use of 
olanzapine. 
 
2.3  Behavioural testing apparatus  
The zero maze was a circular apparatus with a circumference of 105cm that was 
raised 72cm from the ground. It was divided into four equal-sized quadrants – two closed, 
and two open.  The two closed sections had a 25-cm-tall black metal wall on each side, 
whereas the two open sections had a low clear Perspex lip on each side that was 1cm tall. The 
floor in the closed sections was painted black, and in the open sections it was painted white.  
The light-dark box comprised two 30 x 20 x 30 cm high compartments which were 
separated by a wooden partition containing a 10 x 10 cm opening that could be closed by 
means of a removable horizontal slide. Each compartment was covered by a hinged lid that 
was constructed from wood for the dark compartment and clear Perspex for the light 
compartment. The box sat on a 100 cm-high table beneath dim fluorescent lighting.  
The Y maze was 10 cm wide and 14 cm high throughout, and consisted of a 30 cm 
stem and two 45 cm long arms with an angle of 120 between them. A transparent Perspex 
hinged lid covered the maze. Each arm contained a removable black or white aluminium 
insert, which occupied the width, height, and 40 cm of the length of the arms. 
The open field was a wooden box that was 60 x 60 x 30cm tall. It comprised of a 
black painted wooden floor divided into 16 numbered squares (15 x 15cm) by means of a grid 




2.4   General procedure 
Subjects were weaned at postnatal day (PND) 28. They were then housed in standard 
cages of same-sexed groups of three or four individuals with free access to drinking water. At 
PND70, treatment of olanzapine (low, medium or high) via drinking water for experimental 
subjects or 0.1M acetic acid via drinking water for control subjects began for a total of 42 
days until PND112. All rats were weighed and their water intake measured every seven days. 
After 21 days of treatment at PND91 and 42 days of treatment at PND112, rats began their 
behavioural assessments on consecutive days. Each rat was tested in a zero maze, light-dark 
box, open field, and Y-maze, in order to assess any sex differences following olanzapine 
treatment that may manifest in the rats’ behaviour, such as anxiety, locomotor activity, or 
working memory. Following each rat’s trial, the apparatus was sprayed with a 4% solution of 
Powerquat Blue disinfectant, and wiped dry with paper towels. The order of testing was 
randomised for each animal as a counterbalancing measure, and continued until PND115.   
In the zero maze, each rat was placed on a closed area of the maze and then it’s 
entries into the open and closed areas were counted as well as, every three seconds (indicated 
by an auditory signal delivered through an ear-piece), whether it was occupying an open or 
closed area.  
In the light-dark box, the rat was placed in the dark compartment and the time it took 
for it to first emerge into the light compartment it was recorded.  This was followed by 
records of entries into and occupancy of (every three seconds) the light side of the apparatus.  
In the open field, every three seconds it was noted which numbered square the rat was 
occupying, and if it was engaged in behaviour such as rearing or grooming.  From the 
occupancy data, it was subsequently possible to count the number of times the rat was seen in 
one of the four centre or corner squares, and to also indirectly determine the distance 
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travelled (ambulation) by counting the number of times it was occupying a different square 
from that occupied during the preceding three second period (as per Hughes et al., 2014). 
 In the Y-maze, the number of entries into and time spent in each arm was recorded, 
as well as whether the first arm entered was novel or familiar. A three second timer was used 
so that behaviours could be recorded at regular intervals and after each individual trial, the 
apparatus were cleaned to stop olfactory smells interfering with behaviour.  
The use of a momentary time-sampling procedure for recording behaviour in each 
type of apparatus is an accurate and reliable way of measuring frequencies and duration of 
responses (Powell et al., 1977; Detke et al., 1995).   
 
2.4.1  Zero maze testing 
Each rat was placed in a closed area of the zero maze. For five minutes, entries into 
and time observed in the open and closed areas were recorded. Entries were defined as a 
transition involving all four paws. The zero maze was developed to eliminate the ambiguous 
centre region of the elevated plus maze thereby allowing uninterrupted, continuous 
movement through the apparatus. Rodents have an innate tendency to avoid brightly lit areas 
and open spaces. The zero maze is a test of anxiety in rodents which has been 
pharmacologically validated with anxiolytic and anxiogenic drugs, and is based on this innate 
avoidance and on the spontaneous exploratory behaviour of rodents in response to mild 
stressors such as a novel environment, light, or both (Bourin et al., 2003; Acevedo et al., 
2014; Kulesskaya & Voikar, 2014). Therefore, a natural conflict between the tendency of the 
animal to explore, and their fear/defensive behaviour to avoid the unfamiliar occurs when an 
animal is exposed to an unfamiliar environment or novel object (Bourin et al., 2003). When 
allowed to make a choice between two novel areas, closed areas are preferred (Braun et al., 
2011). Therefore, percentage of time spent in the open areas reflects anxiety, where increases 
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in time spent in open areas are interpreted as decreased anxiety (Braun et al., 2011; Pahkla et 
al., 2000; Shepherd et al, 1994). 
 
2.4.2  Light-dark box testing 
Each rat was placed in the dark compartment of the light-dark box for 30 seconds, 
with the slide separating the compartments in place. The slide was then withdrawn, and the 
rat was allowed free access to both compartments for five minutes. The latency of first 
entering the light side, the numbers of entries into and times observed in the light side were 
recorded. Entries were defined as a transition involving all four paws. As for the zero maze, 
higher anxiety is reflected in avoidance of the light side and preference for the dark. 
 
2.4.3  Open field testing 
Each rat was placed in the centre of an open field, a model that resembles the natural 
conflict in rats between the inclination to explore a new environment and to avoid bright, open 
areas. For five minutes, frequencies of behaviour the rat was engaged in, such as rearing, 
walking, grooming or remaining immobile, were recorded. Occupancy of each square involved 
all four paws. Occupancy of different squares was also noted, especially occupancy of corner 
and centre squares. This apparatus allows evaluation of locomotor activity, and it may also be 
used as an anxiety-related model. At the end of each test, the number of faecal boluses left in 
the open field were counted as another measure of anxiety. 
 
2.4.4  Y-maze testing  
Each rat was placed in the stem of the Y-maze, with one arm containing a white 
insert, and the other arm containing a black insert. After a five minute acquisition trial, in 
which the rat was allowed free access to both arms, the rat was removed and the black and 
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white inserts were replaced with two new clean black inserts. The rat was then immediately 
returned to the stem for a three minute retention trial. During this test, the number of entries 
into the changed and unchanged (novel/familiar) arms were recorded, as was the number of 
times observed in each arm and the stem. Entries were defined as a transition involving all 
four paws. The white or changed/novel arm was alternated for each trial as a 
counterbalancing measure. The Y-maze is used to assess spatial working memory in rodents 
by the pattern of arm entries the rodent makes. Continuous spontaneous alternation 
behaviour, a phenomenon based on rodents’ tendencies to enter a less recently visited arm 
over the course of several consecutive entries, is achieved when a rodent enters a new or 
novel arm instead of returning to the arm visited previously on consecutive opportunities. In 
order for this to occur, the animal must remember which arm it previously entered, enabling 
it to alternate its choice on the subsequent trial. Ability to recognise the changed or novel arm 
is a measure of short-term spatial memory (Hughes & Maginnity, 2007). This phenomenon 
has been ascribed to several different mechanisms, including habituation to novelty, curiosity 
and a tendency to explore novel environments, and spatial working memory (Hughes, 2004; 
Heredia-Lopez et al., 2016; Bak et al., 2017). From the total entries and time spent in each 
arm, it is possible to calculate the time spent and percentage of entries into the novel arm, as 
opposed to the unchanged or familiar arm.  
 
2.5  Statistical analysis 
All responses were subjects to separate 4 (dose) x 2 (sex) x 2 (test) ANOVAs. Where 







3.1  Behavioural results 
All outcomes for the effects of sex (male or female), treatment dose and test (test 1 and 2, 
repeated measure) are shown in Table 1. Actual doses of OLA were 6 (low), 11 (medium) 
and 15 (high) mg/kg/day.  
 
Table 1. 
           
 
           Mean ± SEM Values of all Responses in the Zero Maze, Light-Dark Box, Open Field and Y-maze for Male and 
Female Rats in Each Treatment Group in the First Test and Second Tests at PND 91 and PND 112  
            
Measure Treatment  Sex Test     
 
Control Low Medium High F(3,156) Male Female F(1,158) Test 1 Test 2 F(1, 158) 
 
n=20 n=20 n=20 n=20   n=40 n=40   n=80 n=80   
Zero maze 





  % Open Entries 33.01(4.29) 21.5(4.01) 21.32(3.97) 25.42(4.47) 1.726 21.58(2.97) 29.04(2.95) 3.211 25(2.95) 25.63(3.03) 0.023 
  % Open Observationsa 7.68(1.55) 5.35(1.45) 4.23(1.11) 4(0.89) 1.767 4.61(0.87) 6.01(0.95) 1.224 4.38(0.78) 6.25(1.02) 2.196 











  % Light Entries 49.75(1.35) 51.74(0.35) 51.93(0.5) 50.72(0.28) 1.745 50.7(0.73) 51.37(0.23) 0.752 51.24(0.22) 50.84(0.73) 0.272 
  % Light Observations 30.98(2.13) 33.5(1.93) 42.23(2.08) 36.95(2.04) 5.689*** 34.38(1.67) 37.45(1.32) 2.269 36.34(1.45) 35.19(1.58) 0.505 
  First Emergence 
Latency 18.56(3.8) 21.15(4.7) 11.23(1.69) 12.3(1.78) 2.166 18.7(2.67) 12.93(1.89) 3.875* 19.85(2.62) 11.68(1.88) 0.931 











  Ambulationb 39(2.66) 37.33(2.01) 41.63(2.23) 37.5(2.17) 0.923 34.81(1.56) 42.91(1.54) 15.305*** 41.49(1.54) 36.24(1.63) 6.429* 
  Rearinga,b 21.73(2.17) 18.83(1.6) 24.9(1.69) 18.83(1.64) 3.535* 20.56(1.34) 21.08(1.25) 0.092 22.18(1.33) 19.46(1.24) 2.565 
  Centre Occupancy 5.93(1.94) 3.93(0.43) 5.4(0.76) 4.3(0.43 0.719 4.74(0.39) 5.04(1.01) 0.074 3.93(0.29) 5.85(1.04) 3.061 
  Corner Occupancyb 63.6(2.64) 65.55(2.06) 60.6(1.77) 64.23(1.87) 1.022 66.03(1.4) 60.96(1.53) 5.975* 62.95(1.34) 64.04(1.64) 0.276 
  Groominga 1.53(0.28) 3.65(0.86) 3.28(0.58) 2.55(0.41) 3.225* 2.14(0.33) 3.36(0.47) 5.529* 3.85(0.49) 1.65(0.27) 17.832*** 
  Faecal Boluses 0.35(0.2) 1.18(0.42) 0.35(0.19) 0.58(0.24) 2.115 0.99(0.25) 0.24(0.12) 7.834** 0.79(0.23) 0.44(0.16) 1.706 











  First Choice Novelc 1.05(0.06) 1.28(0.08) 1.25(0.07) 1.23(0.07) 1.413 1.14(0.04) 1.26(0.05) 1.197 1.2(0.05) 1.2(0.05) 1.051 
  % Novel Entries 63.15(2.75) 56.54(2.26) 57.05(2.44) 61.03(2.22) 1.71 59(1.94) 59.8(1.52) 0.07 59.4(2.09) 59.43(1.32) 0.005 
  % Novel Observations 58(4.04) 55.28(3.89) 56.44(3.42) 59.2(4.45) 0.22 56.57(2.99) 57.88(2.43) 0.14 56.57(3.13) 57.91(2.25) 0.143 
  Total Arm Entries 4.13(0.42) 4.38(0.38) 5.3(0.37) 4.45(0.36) 1.846 4.05(0.26) 5.08(0.26) 7.492** 4.25(0.29) 4.88(0.25) 2.762 
            *p<0.05, **p<0.01, ***p<0.001 
          adose x sex interaction significant (see text), 
b
sex x test interaction significant (see text), 
c





3.2  Zero maze behaviour  
 
3.2.1 Open arm entries 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 
measure. There were also no significant interactions between any of these independent 
variables.  
 
3.2.2 Open arm observations 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 
measure. However, there was a significant dose x sex interaction, F(3, 144) = 2.743, p<0.05, 
outlined in Figure 1. Female control rats were observed significantly more often in open arms 
than female rats in all other treatment groups, and control males and males in the medium and 
high treatment groups. Male rats in the low treatment group were observed significantly more 
often in the open arms than medium and high treated male rats, but not control rats. Control 
female rats were observed significantly more often in open arms than their male counterparts, 
while the reverse was true for rats in the low treatment group. There was no significant sex 






Figure 1. Effect of sex and dose on open area observations in the zero maze. Error bars 
represent ±1 standard error of the mean.  
Note. abcdef difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 
for that particular sex. 
 
 
3.3  Light-dark box behaviour 
3.3.1 First emergence latency 
As shown in Table 1, there was a significant main effect of sex on first emergence latency in 
the light-dark box. Males took significantly longer to emerge into the light compartment than 
females. However, there were no significant main effects for dose or test, and there were no 
significant interactions between any of these independent variables.  
 
3.3.2 Entries into light 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 

















































3.3.3 Observations in light  
As shown in Table 1, there was a significant main effect of dose on the percentage of 
observations in the light compartment. Rats in the medium dose treatment group were 
observed significantly more often in the light compartment than all other treatment groups 
(see Figure 2). Control animals were observed least often in light, significantly less than 
medium and high dose groups, but not significantly less than low dose treated rats. However, 
there were no significant main effects for sex or test, and there were no significant 




Figure 2. Effect of dose on percentage of observations in the light compartment in the light-dark 
box. Error bars represent ±1 standard error of the mean. 
Note. ab difference between groups with superscripts in common significant (p<0.05). 




3.4  Open field behaviour 
3.4.1 Ambulation 
As shown in Table 1, there was a significant main effect for both sex and test on levels of 
ambulation in the open field. Females emitted significantly higher levels of ambulation 




























the second. However, this latter result is more appropriately considered in the light of a 
significant dose x test interaction, F(3, 144) = 5.508, p<0.001, outlined in Figure 3. In the 
first test, control animals showed significantly higher levels of ambulation than animals 
treated with any of the three doses of OLA. In the second test, control animals ambulated 
significantly less frequently than rats in the medium and high treatment groups. Control rats’ 
activity decreased significantly between test 1 and 2; there was a nonsignificant decrease in 
low and high-dose treated rats’ activity, and a nonsignificant increase in medium-dose treated 




Figure 3. Effect of dose and test on ambulation in the open field. Error bars represent ±1 
standard error of the mean. 
Note. abcdef difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 
for that particular test. 
 
 
3.4.2 Rearing  
As shown in Table 1, there was a significant main effect for dose on rearing in the open field. 
This may be better described in terms of a significant dose x test interaction F(3, 144) = 
4.077, p<0.01 (see Figure 4). In the first test, control rats reared significantly more often than 






































more than low-dose, control, and high-dose treated rats, and rats in the high-dose treatment 
group reared significantly less than control rats. Rearing significantly decreased from test 1 to 
test 2 for both control rats and rats in the high-dose group, however, there was a 
nonsignificant increase in rearing for low and medium-dose treated rats. There was also a 
significant dose x sex interaction, F(3, 144) = 3.822, p<0.01. Females in the medium-dose 
group reared significantly more often than rats treated with low and high-dose OLA, as did 
control rats (see Figure 5). However, control males reared significantly less frequently than 





Figure 4. Effect of dose and test on rearing in the open field. Error bars represent ±1 standard 
error of the mean. 
Note. abcdefgh difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 


































Figure 5. Effect of dose and sex on rearing in the open field. Error bars represent ±1 standard 
error of the mean. 
Note. abcde difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 
for that particular sex. 
 
 
3.4.3 Centre occupancy 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 
measure. There were also no significant interactions between any of these independent 
variables. 
 
3.4.4 Corner occupancy 
As shown in Table 1, there was a significant main effect of sex on corner occupancy in the 
open field. Males spent significantly more time in corner squares than females. There was 
also a significant dose x test interaction, F(3, 144) = 2.65, p<0.05. In the first test, control 
animals spent significantly less time in the corner squares than rats in the low and high-dose 
group. In the second test, control rats spent significantly more time in the corner squares 
compared to rats in the medium-dose. Occupancy of corner squares increased significantly 































Figure 6. Effect of test and dose on corner occupancy in the open field. Error bars represent ±1 
standard error of the mean. 
Note. abcd difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 




As shown in Table 1, there was a significant main effect of test on grooming. Grooming 
significantly decreased between test 1 and test 2. There were also significant main effects for 
sex and dose on grooming. These results may be better described in terms of a significant sex 
x dose interaction, F(3, 144) = 4.597, p<0.01. Control male rats groomed significantly less 
frequently than male rats in the medium and high-dose group. Low-dose treated females 
groomed significantly more frequently than control, medium and high-dose treated rats. 
Control females and low-dose treated females groomed significantly more often than their 









































Figure 7. Effect of sex and dose on grooming in the first test in the open field. Error bars 
represent ±1 standard error of the mean.  
Note. abcdef difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 
for that particular sex.  
 
 
3.4.6 Faecal boluses 
As shown in Table 1, there was a significant main effect of sex on faecal boluses. Males 
defecated significantly more often than females. However, there were no significant effects of 
dose or test on this measure and there were no significant interactions between any of these 
independent variables.  
 
3.5  Y-maze behaviour 
3.5.1 First choice novel arm 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 
measure. However, there was a significant sex x dose x test interaction, F(3, 136) = 3.115, 
p<0.05, (see Figures 8 and 9). In the first test, female rats in the low treatment group chose 
the novel arm first significantly more than male rats in the low treatment group. Female rats 
in the low treatment group also chose the novel arm first significantly more than females in 































first significantly more often than males in the low treatment group. In the second test, 
control males chose to enter the novel arm first significantly less often than males in the low 
and high treatment groups, but not males in the medium treatment group. There were no 
significant results for females in this test. As seen in Figure 10, there was a significant 
decrease in frequency of choosing the novel arm first between the first and second tests for 
control males and males treated with a medium dose of OLA, and a significant increase for 




Figure 8. Effect of sex and dose on first choice novel arm in the Y-maze in Test 1. Error bars 
represent ±1 standard error of the mean. 
Note. abc difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 

































Figure 9. Effect of sex and dose and test on first choice novel arm in the Y-maze in Test 2. Error 
bars represent ±1 standard error of the mean. 
Note. ab difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 




Figure 10. Effect of sex and dose and test on first choice novel arm in the Y-maze for tests 1 and 
2. Error bars represent ±1 standard error of the mean. 
Note. abcdefghi difference between groups with superscripts in common significant (p<0.05). 
*difference between the drug group indicated and the control group significant (p<0.05) 












































































3.5.2 Novel entries 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 
measure. There were also no significant interactions between any of these independent 
variables.  
 
3.5.3 Novel observations 
As shown in Table 1, there were no significant effects of sex, drug dose or test for this 
measure. There were also no significant interactions between any of these independent 
variables.  
 
3.5.4 Total arm entries 
As shown in Table 1, there was a significant main effect of sex on total arm entries in the Y 
maze. Female rats made significantly more total arm entries than male rats. However, there 
were no significant effects for dose or test, and no significant interactions between any of 
these independent variables. 
 
4 Discussion  
 
4.1   Overview 
The current study sought to examine whether there were (and to what extent there 
were) any sex differences in the behaviours exhibited by male and female rats after acute 
exposure to the commonly used atypical antipsychotic olanzapine. This study also aimed to 
clarify the issue surrounding whether atypical antipsychotics are anxiolytic, anxiogenic or 
have no effect on anxiety, and to determine the extent to which SGA-related impairments in 
locomotor activity and spatial working memory differ dependent on the sex of the animal. 
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The dose (OLA, described below) and testing age (PND91 or PND112) were also examined 
as independent variables. At PND70, subjects were administered either approximately 0, 8, 
12 or 16mg/kg olanzapine. Actual approximate doses were 0, 6, 11 and 15mg/kg OLA, 
referred to as control, low, medium or high dose OLA. Their behaviour was then tested in the 
zero maze light-dark box, Y-maze and the open field at PND91 and PND112 to assess 
differences in anxiety, working memory and general motor activity. It was hypothesised that 
acute exposure to olanzapine will result in different behavioural responses between males and 
females, especially at higher doses. 
 
4.2  Olanzapine effects 
4.2.1  Zero Maze 
  As illustrated in Figure 1, male rats in the low dose OLA group were observed 
significantly more often in the open areas of the zero maze than both medium and high dose 
treated males. This indicates that, for males, a lower dose of OLA is associated with lower 
levels of anxiety when compared to higher doses, as male rats in this group spent more time in 
the aversive open area. However, a clear conclusion of the nature of OLA cannot be drawn for 
males as all three treatment groups were not significantly different from control males. 
Nevertheless, males in the low dose treatment group were observed significantly more often in 
the open areas than females in the same group, suggesting that for this particular dose, males 
were less anxious than females. There were no significant differences in anxiety-related 
behaviour between males and females for any other doses. In contrast, control females spent 
significantly more time in the open areas of the maze than both control males and all other 
female treated rats. This suggests that at baseline, females are less anxious than males, and that 
OLA treatment has an anxiogenic effect on females, as its administration reduced the 




  These results suggest an overall anxiogenic effect of OLA for females, as lower doses 
are associated with increased frequency of open area observations, however there is no clear 
effect for males. In general, these findings suggest an anxiogenic effect of olanzapine. Karl et 
al. (2006) found that antipsychotic medications such as haloperidol and risperidone increased 
anxiety levels in rats, as shown by a decrease in time spent in the aversive areas of the open 
field and the elevated plus maze and mixed findings have been found for the anxiety effect of 
olanzapine on obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD) and 
panic disorder. Evidence suggests that while olanzapine, clozapine, quetiapine and risperidone 
have been seen to improve symptoms, it has also been shown that the same SGAs also 
worsened symptoms in other cases (Moore et al., 1994; Brooke et al., 2005; Rogoz & Skuza, 
2011). Olanzapine may exhibit a therapeutic efficacy in some forms of anxiety such as panic 
disorder, but there is also evidence to suggest that it is not effective in alleviating anxiety-like 
symptoms in generalised anxiety (Locchi et al., 2008). Overall, olanzapine presented as 
anxiogenic for females, however there was no clear response for males. This difference in 
behavioural response between males and females in this measure highlights the distinction 
between the two sexes and the need for further investigations into the extent that males and 
females differ in their drug response.  
 
4.2.2  Light-dark Box 
  Rats in the medium dose treatment group were observed significantly more often in the 
light compartment than all other treatment groups (see Figure 2). Control animals were 
observed least often in light, significantly less than medium and high dose groups, but not 
significantly less than low dose treated rats. This suggests that  rats treated with a medium dose 
of OLA were less anxious compared to rats from all other treatment groups, and control rats 
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and rats in the low dose group were the most anxious. This result indicates that OLA has an 
anxiolytic effect, as frequency of light observations, which are associated with decreased 
anxiety, increases with an increase in dose of OLA. Similarly, control and low dose animals 
were observed significantly less frequently in the light compartment.  
 
  This finding is consistent several studies reporting the anxiolytic effects of olanzapine 
(Mead et al., 2008; Sun et al., 2010). Frye and Seliga (2003) found that both 5 and 10mg/kg 
olanzapine has anxiolytic effects as it reduces fear and enhances social interactions in rats in 
relation to control rats due in part to its effects on serotonin and dopamine D1 and D2 
antagonism. In the Geller-Seifter conflict task, olanzapine has also been found to increase 
licking of an electrified water bottle and inhibit the avoidance response of a conditioned 
avoidance task in rats, suggesting that it may have anxiolytic activity (Moore et al., 1992) and 
reduced the acquisition of conditioned freezing in male rats (Inoue et al., 1996). The anxiolytic 
effects of olanzapine may be due to its antagonistic effects on serotonin 5-HT2A and 
dopaminergic D1 and D2 receptors. It has also been found that SGAs such as olanzapine 
activate brain areas involved in anxiety such as the medial prefrontal cortex and the locus 
coeruleus which in turn activated the hypothalamic-pituitary-adrenal (HPA) axis. The medial 
prefrontal cortex is also involved in working memory, learning, and emotional behaviour 
(Locchi et al., 2008). 
 
4.2.3  Open Field 
4.2.3.1 Anxiety effects 
Rearing 
In terms of rearing, mixed findings were present. As illustrated in Figure 4, in the first 
test, control animals reared significantly more often than all drug-treated animals, however 
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there was no significant difference between any of the three doses. This suggests that while 
the different doses did not have a significant effect, olanzapine in general did appear to 
reduce rearing. An increase in rearing is indicative of decreased anxiousness or increased 
exploratory behaviour and as OLA significantly reduced rearing for drug treated animals 
compared to controls, OLA appeared to have an anxiogenic effect in the first test. In the 
second test, control animals’ rearing significantly decreased compared to the first test. 
Although there were no significant increases in drug treated animals’ rearing, this increase in 
control animals’ anxiety suggests that over time or with age, OLA does have protective effect 
on anxiety for low and medium dose groups only. There is also a significant decrease in high 
dose rats rearing which also indicates an increase in anxiety over time. This may suggest that 
low to medium doses of OLA are protective against increasing anxiety, however a high dose 
does not have the same effect. There may be a specific dose range that is anxiolytic. In 
general, this result suggests an overall anxiogenic effect of OLA in the first test, however for 
low and medium doses of OLA, there appears to be a protective (possibly anxiolytic) effect 
against an increase in anxiety over time or with age. This increased anxiety can be seen as a 
significant decrease in rearing for both control animals and animals treated with a high dose 
in the second test, with respect to the first.  
 
There was also a significant sex x dose interaction effect, as illustrated in Figure 5. 
Female control animals were observed rearing significantly more frequently than rats treated 
with a low or high dose of OLA, but not a medium dose. This suggests that control animals 
were significantly less anxious than rats treated with a low or high dose, on which there 
appeared to be an anxiogenic effect of OLA, but at a similar frequency to rats treated with a 
medium dose of OLA, on which there was no significant effect. This result shows that there 
is no apparent trend in treatment and it is therefore not clear whether olanzapine has a direct 
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effect on anxiety for this measure, as both control animals and animals in the medium-dose 
group appeared to be less anxious than low and high dose groups. There were no significant 
differences in rearing behaviour for the different treatment groups for males. However, it was 
found that control females reared significantly more than control males and low-dose males. 
This suggests that at baseline or with a low dose of OLA, females appear to be less anxious 
than males as they exhibit higher levels of rearing. In contrast, males in the high-dose group 
reared significantly more often than their female counterparts, suggesting with a high dose of 
OLA, females appear to be more anxious than males. This is an interesting finding as it 
suggests that OLA has an anxiogenic effect on females at higher doses with respect to 
control. This may be an example of females needing a lower dose than males to avoid 
experiencing adverse effects such as increased anxiety. This also illustrates the sex 
differences in response to OLA, as there is a large disparity between male and female anxiety 
responses for this treatment group. This dose appears to have an aversive effect on females 
compared to males in the same group, and control females.  
 
Corner occupancy 
As shown in Figure 6, in the first test, low and high-dose animals were observed in 
the corner squares significantly more frequently than control animals, but not from each other 
or from medium dose animals. This suggests a general anxiogenic effect of OLA as it 
increased occupation of corner squares and therefore anxiety of two of the three OLA 
treatment groups. However, specific doses of OLA did not have a distinct effect on anxiety-
like behaviour. Occupancy of the corner squares is considered an anxiety-related behaviour 
as it allows the rat to avoid aversive bright, open spaces. Increased time spent in these areas is 
indicative of an anxious rat. In the second test, control animals and low dose animals were 
observed significantly more frequently in the corners of the open field compared to medium 
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dose animals. There was not a significant reduction in corner occupancy for either the low or 
medium dose groups, however there was a significant increase in corner occupancy for 
control animals. This suggests that over time, controls became more anxious, and this 
increase can account for its difference with the medium dose group. Overall, there is no 
significant distinct change between any of the OLA treatment groups, suggesting a protective 
(possibly anxiolytic) effect from an increase in anxiety-related behaviour as seen in rearing. 
However, this is not a strong effect as there was no significant result for rats in the high dose 
group. Overall, in the first test, OLA appears to elicit an anxiogenic effect for low and high 
doses only, increasing the frequency of observations in the corner squares. However, in the 
second test, control animals’ anxiety-related behaviour increases with respect to the medium 
dose OLA group, suggesting a possible protective effect of olanzapine. There were no 
significant increases in anxiety-related behaviour for the drug treatment groups. For control 
animals, age or repeated exposure to this test appears to have a negative effect on the animals.  
 
In general for rearing and corner occupancy in the open field, these results suggest 
that olanzapine generally appears to have an anxiogenic effect in the first test and this effect 
becomes anxiolytic over time or with age in the second test. It is possible that this is 
protective effect, although there are very mixed findings. This may suggest that while 
initially anxiogenic, olanzapine stops an increase in anxiety-related behaviour. However, 
there were no significant decreases in anxiety related behaviour so it cannot be concluded that 
it reduces anxiety. This could be due to several factors, including the length of time since first 
olanzapine administration in the first and second tests, i.e. first administration was three 
weeks prior to the final administration, and pharmacokinetics may impact the behaviour 
elicited in response to OLA at various stages in this three-week administration, age, or greater 
familiarity of the apparatus. These results consistently suggest that olanzapine elicits an 
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anxiolytic effect over time or with age. It has been suggested that repeated treatment with 
olanzapine initially increases and then decreases the total density of GABAA receptors in the 
prefrontal cortex and thus suggesting an adaptive change over longer treatment periods 
(Locchi et al., 2008). Similarly, it is noted that olanzapine works by rebalancing dopamine 
and serotonin to alleviate the positive, negative and cognitive symptoms of schizophrenia and 
improve mood, thinking and behaviour, however the full benefit may not be seen for six to 12 
weeks after first administration (Eli Lilly & Co., 2006; Li et al., 2007). This is not 
uncommon, as selective serotonin reuptake inhibitors (SSRIs), which are used to treat 
depression and anxiety disorders, often increase anxiety levels before the anxiolytic effect 
becomes evident (Mitchell, 2006; Harmer et al., 2009). Therefore, it may be that initial or 
early exposure to olanzapine as an anxiolytic increases anxiety before decreasing it. The 
different ages at which subjects were tested could also provide an explanation as to why 
olanzapine only appears to be anxiolytic in the second test. Although there is minimal 
evidence investigating the effects of age on olanzapine-induced anxiety, it is reasonable, 
based on the currently study, to suggest that an increase in age may be related to increased 
anxiolytic properties.  However, this may also be due to the time at which the first dose of 
olanzapine was administered and may be purely coincidental. Further research would be 
beneficial here. Thirdly, there is the possibility of practice or learning effects and therefore 
the observed anxiolytic effect may be due to perhaps a decrease in curiosity or reduced 
anxiety upon re-exposure to the test. The previous experience rats had gained in this measure 
may in turn decrease their associated anxiety, as seen in several other studies (Rodgers & 





  A dose x sex interaction effect on grooming in the open field showed that control male 
rats and low dose males groomed significantly less frequently than male rats in the medium and 
high-dose groups. As increased grooming is associated with an increase in anxiety, this result 
suggests that as the dose of OLA increases, frequency of grooming increases and therefore it 
appears to have an anxiogenic effect for males (see Figure 7). For females, animals treated with 
a low dose of OLA groomed significantly more frequently than any other treatment group, 
suggesting that this group exhibited the most anxiety-related behavior. Medium dose females 
groomed significantly less than low dose females but significantly more than high dose 
females, suggesting that as the dose of OLA increases, grooming behaviour decreases, 
indicating an anxiolytic effect of OLA. However, with respect to control females, low and 
medium doses of OLA appear to have an anxiogenic effect, increasing anxiety-related 
behaviour. Control and low dose females groomed significantly more than their male 
counterparts, suggesting that, in general, females are more anxious than males for these groups 
only. Overall, OLA appears to have an anxiogenic effect on males and females with respect to 
controls, however grooming decreases with an increased dose of OLA. This is an interesting 
result as, in general, females are seen to be less anxious than males. This reversal in anxious 
behaviour may be a result of OLA and its anxiogenic effect on females. As seen for the zero 
maze and rearing in the open field, OLA appears to increase anxiety, especially in females.  
 
Summary 
  There were overall mixed findings with regards to the effect of dose on anxiety. Firstly, 
for some measures, olanzapine was associated with an anxiolytic effect. Light occupancy in the 
light-dark box and over time or with age for rearing and corner occupancy in the open field all 
showed evidence of an anxiolytic effect of olanzapine. Secondly, however, for other measures, 
olanzapine was associated with an anxiogenic effect. Open arm observations in the zero maze 
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decreased with a higher dose of OLA and grooming also increased as olanzapine dose 
increased, suggesting that olanzapine increased anxious behaviours for these measures. Thirdly, 
both rearing and corner occupancy showed both anxiogenic and anxiolytic effects. In general 
for rearing, OLA appears to be initially anxiogenic. Female controls reared more than male 
controls, suggesting that males were more anxious at baseline, however males treated with a 
high dose of OLA were seen to engage in rearing more often than females in the same 
treatment group, suggesting an anxiolytic effect of OLA for males but not females. In the 
second test, however, rearing reduced only for control animals, suggesting a protective factor of 
OLA. In terms of corner occupancy, while similarly initially anxiogenic, olanzapine appears to 
have an anxiolytic effect over time, as the dose increases, anxiety decreases.  
 
4.2.4.2 Locomotor activity 
As illustrated in Figure 3, it was found that in the first test, control animals showed 
significantly higher levels of ambulation than all drug-treated animals, however, there were 
no significant differences between any of the specific doses of OLA. This suggests that 
olanzapine does significantly reduce ambulation, but it is not clear to what extent different 
doses of OLA impact this reduction. However, in the second test, control animals exhibited 
significantly less locomotor activity than rats in the medium and high dose groups, indicating 
that while there was no significant change in the drug treatment groups between tests, 
locomotor activity had significantly reduced for control animals. Rats in the medium dose 
group were significantly more active than low and high dose treated rats. This suggests that 
an olanzapine-related effect on locomotor activity had become evident over time or with age. 
 
This lack of olanzapine-related effect between test 1 and test 2 for drug-treated 
animals may be a result of OLA use, which appears to have a similar effect on locomotor 
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activity over time or with age. Research by Seliger (1977) in which 50, 100 and 150 day old 
rats were tested in either a black or white open field found that, while defecation scores 
remained the same over both trials, ambulation scores decreased for all animals. It is possible 
that this negative effect of total ambulation scores as seen in the first test may also be due to 
olanzapine-related locomotor impairment in rats, mice and zebrafish, which has been 
reported in several studies (Hillebrand et al., 2005; Duncan et al., 2006; Giacomini et al., 
2006; Stefanidis et al., 2009; Evers et al., 2010; van der Zwaal et al., 2010; Zhang et al., 
2014). Comparable results have also been found in humans (Callaghan et al., 1997; 
Putzhammer et al., 2005; Roerig et al., 2005). This is common with all antipsychotic 
medications including SGAs due to their effect on brain dopamine neurons. While these 
effects are less severe for SGAs compared to conventional antipsychotics such as haloperidol, 
they are still apparent (Tran et al., 1997; Leucht et al., 1999). Destruction of brain 
dopaminergic neurons causes Parkinson’s disease, the most common movement disorder 
characterised by bradykinesia, tremor, rigidity and postural imbalance. Olanzapine has 
exhibited a range of receptor affinities including those for dopamine D1-5 receptors. 
Olanzapine has also been found to worsen motor symptoms of Parkinson’s disease (Molho & 
Factor, 1999) and reduce cocaine- and dizocilpine-related hyperlocomotion (Meil & 
Schechter, 1997; Ninan & Kulkarni, 1999). Reduced locomotor activity as a result of 
olanzapine use may also be one possible explanation as to why SGAs, in particular 
olanzapine, have such a profound effect on weight gain (van der Zwaal et al., 2010; Evers et 
al., 2010; van der Zwaal et al., 2012). It is possible that, in terms of the current study, 
locomotor activity deteriorate for control animals in the second test due to a learning effect in 
which the previous experience rats had gained in this measure may in turn decrease their 
associated desire to re-explore their surroundings and therefore reduce exploratory activity. If 
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this is the case for control animals, it is interesting that ambulation scores for drug treated 
animals in the second test did not follow this trend and also differ significantly.  
 
4.2.4  Y-maze 
In the first test, when first placed in the Y maze, it was found that for female rats, 
olanzapine does not have a significant effect on the frequency of first choosing the novel arm 
as none of the treatment groups are significantly different from controls, however the female 
rats treated with a low dose of OLA chose the novel arm significantly more often than high 
dose females, but not more than any other group (see Figure 8). This indicates that a higher 
dose of OLA may be associated with impairment in spatial working memory when compared 
to a low dose of OLA for females; however this is not significantly different from controls so 
it did not show a significant effect of olanzapine. A similar result was found for males in the 
first test. There was no significant effect of olanzapine for any dose with relation to control 
animals; however male rats treated with a medium dose of olanzapine first chose to enter the 
novel arm significantly more often than rats treated with a low dose of olanzapine. This 
suggests the opposite. That is, that males may need a higher dose of the drug for therapeutic 
efficacy, but this does not result in adverse effects. Females treated with a low dose of OLA 
chose the novel arm significantly more often than males in the same group, suggesting that 
males treated with a low dose of OLA have poorer memory recall than female rats based on 
their capacity to remember the novel arm. In agreement with the previous statements, this 
suggests that a lower dose of OLA is more beneficial for females but not males. However, 
this result was found for this group only. In the second test, males treated with both a low and 
a high dose of OLA entered the novel arm first significantly more often than control males, 
but not males in the medium-dose group (see Figure 9). This suggests that olanzapine 
treatment has a positive effect on spatial working memory as males in these groups were 
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better able to remember which arm was novel compared to control animals. There was no 
significant result for females in this test.  
 
As seen in Figure 10, there was a significant decrease in frequency of first choosing 
the novel arm first between the first and second tests for control males and males treated with 
a medium dose of OLA. This suggests a reduction in ability to recognise the novel arm first. 
The reverse was true for males treated with a low dose and females treated with a high dose 
of OLA, whose ability to recognise the novel arm upon first entering the Y maze increase. 
This indicates that for control and medium dose males, there may be a practice effect 
associated with the Y maze, or that there is an olanzapine-related negative effect on spatial 
working memory, but for low dose males and high dose females, olanzapine appears to 
improve spatial working memory over time or with age.  
 
Overall, this finding suggests that there is a both a positive and negative dose-
dependent effect of olanzapine on spatial working memory, however these findings are very 
mixed making it difficult for conclusions to be drawn. There are contradictory findings 
regarding the effect of olanzapine on spatial working memory. Skarsfeldt (1996) found that 
olanzapine did indeed disrupt learning in the Morris water maze and Ortega-Alvaro (2006) 
also found a negative effect of olanzapine on working memory in the radial arm maze, while 
Rosengarten & Quartermain (2002) found that olanzapine had no effect on learning 
processes. A study by Terry et al. (2002) found that after a 4 day washout period, exposure to 
olanzapine for 45 days did not produce any significant effects on spatial learning, however 
after a 90-day administration, a persistent impairment in the water maze task was observed. 
As increases in dopamine promote working memory performance and dopamine agonists 
facilitate working memory, it makes sense to assume that dopamine receptor antagonists, 
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such as olanzapine, may impair working memory performance. However, it is possible that 
the olanzapine-related impairment in working memory could be due to the sedative effects of 
SGAs (Ortega-Alvaro, 2006).  
 
4.3  Sex effects 
4.3.1  Light-dark Box 
  In the light-dark box, males took significantly longer to emerge into the light 
compartment compared to females. Longer first emergence latencies suggest higher levels of 
anxiety (Braun et al., 2011). As rats feel comfortable in enclosed spaces, rapid entry into the 
light compartment which is generally avoided by anxious rats indicates that females were, 
overall, less anxious on this measure than male rats. This result is consistent with Archer (1975) 
who also found that female rats and hamsters emerge sooner into a novel or exposed 
environment compared to males. 
 
4.3.2  Open Field  
Anxiety 
In the open field, it was found that males spent significantly more time occupying 
corner squares than females. This also illustrates the higher levels of anxiety exhibited by 
male rats in this test of anxiety, as they showed a preference for enclosed spaces. The more 
time spent occupying corner squares of the open field indicates an avoidance of open spaces 
and is therefore consistent with the behaviour of an anxious rat. Furthermore, it was also 
found that males defecated significantly more often than females in the open field. This is 
also indicative of increased emotionality and anxiety in male rats (Walsh & Cummins, 1976). 
The combination of decreased movement and increased defecation in males in the open field 
is thought to represent a frightened or fearful animal. Females are consistently shown to be 
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less emotional because of their lower rates of defecation and elevated ambulation scores 
(Meunier & Fischer, 1985) and this study shows consistent results. 
 
Overall, it appears that males were more anxious than females in several measures of 
anxiety based on their innate preference for familiar, enclosed places. Female rats were 
observed significantly more often than male rats in open arms of the zero maze, they emerged 
significantly faster into the open compartment of the light-dark box, and spent less time in the 
corner squares of the open field. Male rats also defecated significantly more than female rats. 
This is consistent with several studies which report the increased emotionality of males 
compared to females, and that females appear to be more active and less anxious than male 
rats (Gray, 1971; Archer, 1973, 1975). However, in the open field, generally, male rats were 
observed to engage in grooming significantly less often than female rats. As an increase in 
grooming is also associated with an increase in anxiety levels, this result suggests the 
opposite. That is, that female rats appeared to be more anxious than males for this measure 
(Walsh & Cummins, 1976; Diaz-Moran et al., 2014). This appears to be due to due to the 
effect of OLA.  
 
Locomotor activity 
With regard to the effect of sex on locomotor activity, females were observed to have 
significantly higher levels of ambulation in the open field compared to males. This result is 
consistent with several studies (Archer, 1975; Seliger, 1977; Meunier & Fishcer, 1985; Slob 
et al., 1986) who all found increased ambulation in females compared to males. This 
increased locomotor activity may also be an index of an increase in exploratory behaviour, 
and a decrease in anxiety in female rats. Percentage of entries and transitions in the zero 
maze, Y maze and the light-dark box are also measures of ambulation, but were not 
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significant when assessing sex differences. This increased locomotor activity may also be an 
index of an increase in exploratory behaviour, and a decrease in anxiety in female rats, 
consistent with the reduced anxiety-like behaviour in female as opposed to male rats.  
 
4.3.3  Y-maze 
In terms of the effect of sex on total arm entries in the Y maze, in the first test, female 
rats made significantly more total arm entries than male rats. Although this does not suggest a 
learning deficit, it does suggest that female rats showed increased locomotor activity and 
perhaps a reduction in anxiety, which is consistent with previous findings in the current 
study, and previous research stating that females appear to be more active and less anxious 
than male rats (Gray, 1971; Archer, 1973, 1975; Seliger, 1977; Slob et al., 1986).  
 
4.4  Test/age effects 
4.4.1  Open Field 
  A significant main effect of test for ambulation in the open field showed that all 
subjects ambulated significantly more often in the first test than in the second. However, this 
result is more appropriately explained in terms of a significant dose x test interaction, as 
described above.  
 
  A main effect of test for grooming in the open field was also found. Grooming 
significantly decreased between test 1 and test 2, suggesting that there is a decrease in anxiety 
in the open field between these two tests. Furthermore, this indicates an anxiolytic effect of 




4.5  Limitations  
There are a number of limitations that have become clear upon the completion of this 
study that are worth mentioning. Firstly, a histological analysis of the rats’ brains was not 
performed upon the completion of the experiment. This would have provided greater insight 
into the structural and chemical changes as a result of olanzapine treatment and how this 
differed based on the sex of the animal, such as dopamine and serotonin. Changes in 
serotonin could account for the anxiety, memory or locomotor effects found in this 
experiment as it is implicated in each of these functions (Graeff et al., 1996; Karl et al., 2006; 
Locchi et al., 2008). As both dopamine and serotonin levels are altered by olanzapine, this 
analysis could reveal some interesting and important changes. However, the focus of this 
thesis was not on anatomical and neurochemical changes but on behavioural measures.  
 
Secondly, long-term effects of olanzapine use were not examined. This is an 
important limitation as it is possible that humans may be prescribed SGAs such as olanzapine 
in the long term, and effects seen in the present study may only be preliminary when 
considering the long-term use of the drug. Furthermore, it is important to investigate possible 
sex differences associated with long term use as any differences or the extent of the 
differences may change over the course of several years. However, because this study 
focused on the effects in early adulthood, this limitation is not a significant exclusion. 
 
Thirdly, observer reliability tests were not used to ensure all observations were 
consistent. It is possible for an observer or in this case, the experimenter, to subconsciously 
observe what they believe they should be seeing while observing the animals’ behaviour, 
rather observe than what is truly occurring (Kaufman & Rosenthal, 2009). Therefore, it is 
possible that mistakes were made during the experiment as notation was made every 3 
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seconds, and this fast pace may have contributed to mistakes in what the researcher thought 
they had seen and thus, what was recorded and analysed (Kaufman & Rosenthal, 2009). This 
may result in a question as to whether results recorded were in fact reliable. In order to get 
around this limitation, it is suggested that the use of a second observer would be useful to 
conduct inter-observer reliability tests to assess the reliability of the experimenter and ensure 
all recorded results were accurate (Kaufman & Rosenthal, 2009). However, this was not 
included in the current study. Even though this is a limitation, it does, however, mean that a 
single experimenter would be consistent throughout the entirety of the experiment.  
 
Lastly, extraneous variables related to the room in which animals were tested is a 
limitation of the current study. It is important to note that the timing of the experiments 
varied from day to day due to time constraints and other commitments of the experimenter. 
Some animals were tested early in the morning and others late at night. The timing of the 
testing is an important limitation as it can affect locomotion and anxiety responses (Kaya, 
Karakaş, & Coşkun, 2011). However, these variables were not always present and therefore 
they may not have had a strong enough implication on the results. Furthermore, other rats 
which were not tested were in the same room as the rat being tested and it is possible that the 
smell of the other rats could have directed the attention of the animals elsewhere. Steps were 
taken to separate rats as much as possible to reduce this issue.  
 
4.6  Future directions 
The results of this study highlight the fundamental differences between males and 
females in their responses to anxiety, locomotor activity and spatial working memory, and the 
effects of olanzapine on these. There are several differences in sex, dose and the age at which 
animals were tested that suggest that these differences need to be addressed to reduce the risk 
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and increase the benefit associated with SGAs. The current study illustrates some important 
facts that will require additional research. Firstly, the limitations of this study need to be 
addressed. A histological analysis would be useful to identify brain changes as a result of 
olanzapine exposure and provide a more comprehensive understanding of sex differences in 
olanzapine treatment and how this may explain behaviour. It is also suggested that the time 
frame in which animals were exposed to olanzapine be lengthened to investigate sex 
differences and chronic exposure, and whether the age of the animals plays an important role. 
Future research should focus on replication of the current experiment to ensure accurate, 
reliable and generalisable findings, perhaps non-inclusive of the test factor in order to avoid 
any issues that may be correlated with learning effects upon re-exposure of rats to the 
different types of apparatus.  
 
4.7  Conclusions 
The aim of this experiment was to examine whether there were any sex differences in 
the behaviours exhibited by male and female rats after acute exposure to the commonly used 
atypical antipsychotic olanzapine. This study also aimed to clarify the issue surrounding 
whether atypical antipsychotics are anxiolytic, anxiogenic or have no effect on anxiety, and 
to determine the extent to which SGA-related impairments in locomotor activity and spatial 
working memory differ dependent on the sex of the animal. It can be concluded that there are 
marked differences in the behavioural responses to olanzapine in males and females. 
Although the exact nature of some of these differences is unclear at present, the fact that they 
exist is obvious. For example, olanzapine elicited a clear anxiogenic effect for females in the 
zero maze, however effects on males were unclear and females appeared to experience 
anxiety-like symptoms at higher doses that were significantly different to males when looking 
at rearing in the open field. There is strong evidence to suggest that olanzapine has an 
64 
 
anxiogenic effect on anxiety-related behaviours, however anxiolytic effects are still apparent, 
as highlighted in the light-dark box and in the open field for rearing, corner occupancy and 
grooming. Nevertheless, it is clear that it does have an effect on anxiety-related behaviour. 
Olanzapine also has an overall negative effect on locomotor activity over time, though this 
effect is dose dependent. With regard to spatial working memory, there are also considerably 
contradictory findings, with the suggestion of a negative effect of olanzapine on memory over 
time, however it appears that females may be more resilient to this effect than males. Overall, 
it can be concluded that the response of males and females to olanzapine differs in many 
cases. These results highlight these marked differences and suggest that a dose that may be 
safe and efficacious for males may not be the same dose that is safe and efficacious for 
females. Behavioural responses in anxiety, locomotor and working memory tasks varied 
dependent on the sex of the animal. These results may have implications for the use of the 
drug with humans as it has been proven that females do experience significantly more 
adverse effects of the drug with respect to males. This may be a result of the given dose of the 
drug; reducing the dose for female patients may result in an improved prognosis, with fewer 
adverse effects and a better efficacy. It is therefore recommended that further research be 
undertaken to determine the extent to which these differences may have an impact on the 




5 References  
 
Acevedo, M., Nizhnikov, M., Molina, J. & Pautassi, R. (2014). Relationship between 
ethanol-induced activity and anxiolysis in the open field, elevated plus maze, light-
dark box, and ethanol intake in adolescent rats. Behavioural Brain Research, 265, 
203-215.  
 
Aichhorn, W., Whitworth, A., Weiss, E., Hinterhuber, H. & Marksteiner, J. (2007). 
Differences between men and women in side effects of second-generation 
antipsychotics. Der Nervenarzt, 78(1), 45-52.  
 
Aichhorn, W., Whitworth, A., Weiss, E. & Marksteiner, J. (2006). Second-generation 
antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse 
effect profiles? Drug Safety, 29(7), 587-598. 
 
Aichhorn, W., Gasser, M., Weiss, E., Adlassnig, C. & Marksteiner, J. (2005). Gender 
differences in pharmacokinetics and side effects of second generation antipsychotic 
drugs. Current Pharmacology, 3, 73-85. 
 
Aitchison. L., & Hughes, R. (2006). Treatment of adolescent rats with 1-benzylpiperazine: a 
preliminary study of subsequent behavioural effects. Neurotoxicology and Teratology, 
28, 453-458. 
 
Anderson, G. (2008). Gender differences in pharmacological response. International Review 




Archer, J. (1973). Tests for emotionality in rats and mice: a review. Animal Behaviour, 21(2), 
205-235. 
 
Archer, J. (1975). Rodent sex differences in emotional and related behavior. Behavioral 
Biology, 14, 451-479.  
 
Arnold, L., Strakowski, S., Schwiers, M., Amicone, J., Fleck, D., Corey, K. & Farrow, J. 
(2004). Sex, ethnicity, and antipsychotic medication use in patients with psychosis. 
Schizophrenia Research, 66(3), 169-175.  
 
Bak, J., Pyeon, H., Seok, J. & Choi, Y. (2017). Effect of rotation preference on spontaneous 
altneration behaviour on Y maze and introduction of a new analytic method, entropy 
of spontaneous alternation. Behavioural Brain Research, 320, 219-224.  
 
Bantick, R., De Vries, M. & Grasby, P. (2005). The effect of a 5-Ht receptor agonist on 
striatal dopamine release. Synapse, 57(2), 67-75. 
 
Berg, U. (2006). Differences in decline in GFR with age between males and females: 
reference data on clearances of inulin and PAH in potential kidney donors. 
Nephrology Dialysis Transplantation, 21(9), 2577-82. 
 
Becker, J. (1999). Gender differences in dopaminergic function in striatum and nucleus 




Becker, J. & Cha, J. (1989). Estrous cycle-dependent variation in amphetamine induced 
behaviors and striatal dopamine release assessed with microdialysis. Behavioural 
Brain Research, 35, 117–125. 
 
Beierle, I., Meibohm, B. & Derendorf, H. (1999). Gender differences in pharmacokinetics 
and pharmacodynamics. International Journal of Clinical Pharmacology and 
Therapeutics, 37, 529-547.  
 
Bennink, R., Peeters, M., Van den Maegdenbergh, V., Geypens, B., Rutgeerts, P., De Roo, 
M. & Mortelmans, L. (1998). Comparison of total and compartmental gastric 
emptying and antral motility between healthy men and women. European Journal of 
Nuclear Medicine, 25, 1293–1299. 
 
Blehar, M. (1995). Gender differences in risk factors for mood and anxiety disorders: 
implication for clinical treatment research. Psychopharmacology Bulletin, 31, 4687-
4691. 
 
Blin, O., Azorin, J. & Bouhours, P. (1996). Antipsychotic and anxiolytic properties of 
risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of 
Clinical Psychopharmacology, 16(1), 38-44.  
 
Braun, A., Skelton, M., Vorhees, C. & Williams, M. (2011). Comparison of the elevated plus 
and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of 





Brooke, N., Wiersgalla, M. & Salzman, C. (2005). Atypical uses of atypical antipsychotics.  
Harvard Review of Psychiatry, 13(6), 317-339. 
 
Buchanan, F., Myles, P. & Cicuttini, F. (2009). Patient sex and its influence on general 
anaesthesia. Anaesthesia and Intensive Care, 37(2), 207-218.  
 
Callaghan, J., Cerimele, B., Kassahun, K., Nyhart, E. Jr., Hoyes-Beehler, P. & Kondraske, G. 
(1997). Olanzapine: interaction study with imipramine. Journal of Clinical 
Pharmcology, 37(10), 971–978. 
 
Callaghan, J., Bergstrom, R., Ptak, L. & Beasley, C. (1999). Olanzapine: pharmacokinetic 
and pharmacodynamic profile. Clinical Pharmacokinetics, 37(3): 177-93. 
 
Carlsson, M. & Carlsson, A. (1988). A regional study of sex differences in rat brain 
serotonin. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 12, 53-
61.  
 
Chen, M., Lee, S., Ng, M., Schuirmann, D., Lesko, L. & Williams, R. (2000). 
Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues 
in clinical pharmacology and biopharmaceutics. Clinical Pharmacology and 
Therapeutics, 68(5), 510–521, 2000.  
 
Coker, S. (2008). Drugs for men and women – how important is gender as a risk factor for 




Conley, R. & Mahmoud, R. (2001). A randomized double-blind study of respiridone and 
olanzapine in the treatment of schizophrenia or schizoaffective disorder. American 
Journal of Psychiatry, 158(5), 765-774. 
 
Cooper, S., Drolet, D. & Dugal, R. (1984). Comparative bioavailability of two oral 
dormulations of flurazepam in human subjects. Biopharmaceutics and Drug 
Disposition, 5(2), 127-139.  
 
Davey, K., O’Mahony, S., Schellekens, H., O’Sullivan, O., Bienenstock, J., Cotter, P., Dinan, 
T. & Cyran, J. (2012). Gender-dependent consequences of chronic olanzapine in the 
rat: effects on body weight, inflammatory, metabolic and microbiota parameters. 
Psychopharmacology, 221, 155-169. 
 
De Oliveira, I. & Juruena, M. (2006). Treatment of psychosis: 30 years of progress. Journal 
of Clinical Pharmacy and Therapeutics, 31, 523-534. 
 
DeBold, J. & Miczek, K. (1985). Testosterone modulates the effects of ethanol on male 
mouse aggression. Psychopharmacology, 86, 286-290. 
 
DeCherney, A., Nathan, L., Goodwin, T., Laufer, N. & Roman, A. (2006). Current diagnosis 




Detke, M., Rickels, M. & Lucki, I. (1995). Active behaviours in the rat forced swimming test 
produced by serotonergic and noradrenergic antidepressants. Psychopharmacology, 
(121), 66-72. 
 
Dey, S., Menkes, D., Obertova, Z., Chaudhuri, S. & Mellsop, G. (2016). Antipsychotic 
prescribing and its correlates in New Zealand. Australasian Psychiatry, 24(4), 360-
364. 
 
Dewing, P., Chiang, C., Sinchak., K., Sim, H., Fernagut, P., Kelly, S., Chesslet, M., 
Micevych, P., Albrecht, K., Harley, V. & Vilain, E. (2006). Direct regulation of adult 
brain function by the male specific factor SRY. Current Biology, 16, 415-420. 
 
Drago, F., Contarino, A., Marino, R., Anzallo, C., Valerio, C., Rampello, L., Raffaele, R. & 
Scapagnini, U. (1997). Effects of acute or chronic administration of risperidone on 
motor and sexual behavior of male rats. Pharmacological Research, 35(1), 17-25. 
 
Duncan, G., Moy, S., Lieberman, J. & Koller, B. (2006). Typical and atypical antipsychotic 
drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a 
genetic model of NMDA receptor hypofunction. Pharmacology, Biochemistry and 
Behavior, 85, 481-491. 
 





Evers, S., Calcagnoli, F., van Dijk, G. & Scheurink, A. (2010). Olanzapine causes 
hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar 
rats. Pharmacology, Biochemistry and Behavior, 97, 163-169.  
 
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., Jorgensen, A., 
Payne, K., Pirmohamed, M., Pushpakom. S., Walley, T., de Warren-Penny, P. & 
Dickson, R.. (2010). The clinical effectiveness and cost-effectiveness of testing for 
cytochrome P450 polymorphisms in patients with schizophrenia treated with 
antipsychotics: A systematic review and economic evaluation. Health Technology 
Assessment, 14, 1–157. 
 
Frye, C. & Seliga, A. (2003). Olanzapine’s effects to reduce fear and anxiety and enhance 
social interactions coincide with increased progestin concentrations of ovarectomized 
rats. Psychoneuroendocrinology, 28, 657-673. 
 
Gandhi, M., Aweeka, F., Greenblatt, R. & Blaschke, T. (2004). Sex differences in 
pharmacokinetics and pharmacodynamics. Annual Review of Pharmacology and 
Toxicology, 44, 499-523. 
 
Gaudry, S., Sitar, D., Smyth, D., McKenzie, J. & Aoki, F. (1993). Gender and age as factors 
in the inhibition of renal clearance of amantadine by quinine and quinidine. Clinical 
Pharmacology and Therapeutics, 54(1), 23-7.  
 
Gee, S. & Croucher, M. (2011). Older New Zealanders and antipsychotic medications 






Gex-Fabry, M., Balant-Gorgia, A. & Balant, L. (2003). Therapeutic drug monitoring of 
olanzapine: the combined effect of age, gender, smoking, and comedication. 
Therapeutic Drug Monitoring, 25, 46-53. 
 
Giacomini, K., Huang, S. & Tweedie, D. (2010). Membrane transporters in drug 
development. Nature Reviews Drug Discovery, 9(3), 215-236.  
 
Giacomini, N., Rose, B., Kobayashi, K. & Guo, S. (2006). Antipsychotics produce locomotor 
impairment in larval zebrafish. Neurotoxicology and Teratology, 28, 245-250. 
 
Glenthoj, B., Hemmingsen, R., Allerup, P. & Bolwig, T. (1990). Intermittent versus 
continuous neuroleptic treatment in a rat model. European Journal of Pharmacology, 
190(3), 275-286.  
 
Gorski, R., Gordon, J., Shryne, J. & Southam, A. (1978). Evidence for a morphological sex 
difference within the medial preoptic area of the rat brain. Brain Research, 148, 333-
346.  
 
Graeff, F., Guimaraes, F., De Andrade, T. & Deakin, J. (1996). Role of 5-HT in stress, 




Gray, J. (1971). Sex differences in emotional and cognitive behaviour in mammals including 
man: endocrine bases. Acta Psychologica, 35, 29-46. 
 
Green, M., Marshall, B., Wirshing, W., Ames, D., Marder, S., McGurk, S., Kern, R. & Mintz, 
J. (1997). Does risperidone improve verbal working memory in treatment resistant 
schizophrenia? American Journal of Psychiatry, 154(6), 799-804.  
 
Greenblatt, D. & von Moltke, L. (2008). Gender has a small but statistically significant effect 
on clearance of CYP3A substrate drugs. Journal of Clinical Pharmacology, 48(11), 
1350-1355.  
 
Groenewegen, H. (2003). The basal ganglia and motor control. Neural Plasticity, 10, 107-
120. 
 
Gross, J., Friedman, R., Azevedo, M., Silveiro, A. & Pecis, M. (1992). Effect of age and sex 
on glomerular filtration rate measured by 51Cr-EDTA. Brazilian Journal of Medical 
and Biological Research, 25, 129-134. 
 
Haack, A., Seeringer, A., Thurmann, P., Becker, T. & Kirchheiner, J. (2009). Sex specific 
differences in side effects of psychotropic drugs: genes or gender? 
Pharmacogenomics, 10(9), 1511-1526.  
 
Hagg, S., Spigset, O. & Dahlqvist, R. (2001). Influence of gender and oral contraceptives on 
CYP2D6 and CYP2C19 activity in healthy volunteers. British Journal of Clinical 




Hardman, J., Limbird, L. & Gilman, A. (2001). Goodman & Gilman’s the Pharmacological 
Basis of Therapeutics. New York, USA: McGraw- Hill. 
 
Harmer, C., Goodwin, G. & Cowen, P. (2009). Why do antidepressants take so long to work? 
A cognitive neuropsychological model of antidepressant drug action. The British 
Journal of Psychiatry, 195, 102-108. 
 
Heredia-Lopez, F., Alvarez-Cervera, F., Colli-Alfaro, J., Bata-Garcia, J., Arankowsky-
Sandoval, G. & Gongora-Alfaro, J. (2016). An automated Y-maze based on a reduced 
instruction set computer (RISC) microcontroller for the assessment of continuous 
spontaneous alteration in rats. Behavior Research Methods, 48, 1631-1643. 
 
Hill, S., Bishop, J., Palumbo, D. & Sweeney, J. (2010). Effect of second-generation 
antipsychotics on cognition: current issues and future challenges. Expert Review of 
Neurotherapeutics, 10(1), 43-57.  
 
Hillebrand, J., van Elburg, A., Kas, M., van Engeland, H. & Adan, R. (2005). Olanzapine 
reduces physical activity in rats exposed to activity-based anorexia: possible 
implications for treatment of anorexia nervosa? Biological Psychiatry, 58(8), 651–
657. 
 
Hillert, A., Maier, W., Wetzel, W. & Benkert, O. (1992). Risperidone in the treatment of 
disorders with a combined psychotic and depressive syndrome – a functional 




Hines, M., Allen, L. & Gorski, R. (1992). Sex differences in subregions of the medial nucleus 
of the amygdala and the bed nucleus of the stria terminalis of the rat. Brain Research, 
579, 321-326. 
 
Hughes, R. (2004). The value of spontaneous alternation behavior (SAB) as a test of retention 
in pharmacological investigations of memory. Neuroscience and Biobehavioral 
Reviews, 28, 497-505.  
 
Hughes, R. (2007). Sex does matter: comments on the prevalence of male-only investigations 
of drug effects on rodent behaviour. Behavioural Pharmacology, 18(7), 583-589.  
 
Hughes, R., Hancock, N., Henwood, G. & Rapley, S. (2014). Evidence for anxiolytic effects of 
acute caffeine on anxiety-related behavior in male and female rats tested with and 
without bright light. Behavioural Brain Research, (271), 7-15. 
 
Hughes, R. & Maginnity, M. (2007). Cues by male and female hooded rats for locating a 
brightness change. Behavioural Processes, (74), 79-87. 
 
Hutson, W., Roehrkrasse, R. & Wald, A. (1989). Influence of gender and menopause on 
gastric emptying and motility. Gastrointestinology, 96, 11-17.  
 
Ingalhalikar, M., Smith, A., Parker, D., Satterthwaite, T., Elliott, M., Ruparel, K., 
Hakonarson, H., Gur, R., Gur, R. & Verma, R. Sex differences in the structural 
76 
 
connectome of the human brain. Proceedings of the National Academy of Sciences, 
111(2), 823-828.  
 
Inoue, T., Tsuchiya, K. & Koyama, T. (1996). Effects of typical and atypical antipsychotic 
drugs on freezing behaviour induced by conditioned fear. Pharmacology, 
Biochemistry and Behavior, 55(2), 195-201. 
 
Ishida-Tokuda, K., Ohno, Y., Sakamoto, H., Ishibashi, T., Wakabayashi, J., Tojima, R., 
Morita, T. & Nakamura, M. (1996). Evaluation of perospirone (SM-9018), a novel 
serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the 
conditioned fear stress-induced freezing behavior model in rats. Japanese Journal of 
Pharmacology, 72(2), 119-126.  
 
Jovanovic, H., Lundberg, J., Karlsson, P. Cerin, A., Saijo, T., Varrone, A., Halldin, C. & 
Nordstrom, A. (2008). Sex differences in the serotonin 1A receptor and serotonin 
transporter binding in the human brain measured by PET. Neuroimage, 39(3), 1408-
1419.  
 
Juraska, J. (1991). Sex differences in ‘cognitive’ regions of the rat brain. 
Psychoneuroendocrinology, 16, 105-109. 
 
Kadono, K., Akabane, T., Tabata, K., Gato, K., Terashita, S. & Teramura, T. (2010). 
Quantitative prediction of intestinal metabolism in humans from a simplified 
intestinal availability model and empirical scaling factor. Drug Metabolism and 




Karl, T., Duffy, L., O’Brien, E., Matsumoto, I. & Dedova, I. (2006). Behavioural effects of 
chronic haloperidol and risperidone treatment in rats. Behavioural Brain Research, 
171, 286-294.  
 
Kashuba, A. & Nafziger, A. (1998). Physiological changes during the menstrual cycle and 
their effects on the pharmacokinetics and pharmacodynamics of drugs. Clinical 
Pharmacokinetics, 34, 203-218. 
 
Kaufman, B. & Rosenthal, R. (2009). Can you believe my eyes? The importance of 
interobserver reliability statistics in observations of animal behaviour.  Animal 
Behaviour, 78, 1487-1491. 
 
Kaya, A., Karakas, A. & Coskun, H. (2011). The effects of the time of the day and the 
pinealectomy on anxiety-like behaviour in male Wistar rats. Biological Rhythm 
Research, 42(5), 367-383.   
 
Kelly, D., Conley, R. & Tamminga, C. (1999). Differential olanzapine concentrations by sex 
in a fixed-dose study. Schizophrenia Research, 40, 101-104. 
 
Kennedy, M. (2008). Hormonal regulation of hepatic drug metabolising enzyme activity 




Kulesskaya, N. & Voikar, V. (2014). Assessment of mouse anxiety-like behavior in the light-
dark box and open field arena: role of equipment and procedure. Physiology & 
Behavior, 133, 30-38.  
 
Lane, H., Chang, Y., Chang, W., Lin, S., Tseng, Y. & Jann, M. (1999). Effects of gender and 
age on plasma levels of clozapine and its metabolites: analysed by critical statistics. 
Journal of Clinical Psychiatry, 60(1), 36-40. 
 
Leblhuber, F., Neubauer, C., Peichl, M., Reisrcker, F., Steinparz, F., Windhager, E. & 
Dienstl, E. (1993). Age and sex differences of dehydroepiandrosterone sulfate 
(DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer’s 
disease (AD). Psychopharmacology, 111(1), 23-6.  
 
Leucht, S., Pitschel-Walz. G., Amraham, D & Kissling, W. (1999). Efficacy and 
extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, 
risperidone, and sertindole compared to conventional antipsychotics and placebo. A 
meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51-68. 
 
Li, M., Fletcher, P. & Shitij, K. (2007). Time course of the antipsychotic effect and the 
underlying behavioural mechanisms. Neuropsychopharmacology, 32, 263-272. 
 
Li, Z., Ichikawa, J., Dai, J. & Meltzer, H. (2004). Aripiprazole, a novel antipsychotic drug, 
preferentially increases dopamine release in the prefrontal cortex and hippocampus in 




Lieberman, J., Stroup, T., McEvoy, J., Schwartz, M., Rosenheck, R., Perkins, D., Keefe, R., 
Davis, S., Davis, C., Lebowitz, B., Severe, J. & Hsiao, J. (2005). Effectiveness of 
antipsychotic drugs in patients with chronic schizophrenia. New England Journal of 
Medicine, 353(12), 1209-1223.  
 
Locchi, F., Dall’Olio, R., Gandolfi, O. & Rimondini, R. (2008). Olanzapine counteracts 
stress-induced anxiety-like behavior in rats. Neuroscience Letters, 438, 146-149. 
 
Loebstein, R., Lalkin, A. & Koren, G. (1997). Pharmacokinetic changes during pregnancy 
and their clinical relevance. Clinical Pharmacokinetics, 33(5), 328-43. 
 
Lorena, S., Tinois, E., Brunetto, S., Camargo, E. & Mesquita, M. (2004). Gastric emptying 
and intragastric distribution of a solid meal in functional dyspepsia: Influence of 
gender and anxiety. Journal of Clinical Gastroenterology, 38, 230–236. 
 
Luine, V. (2002). Sex differences in chronic stress effects on memory in rats. Stress, 5, 205-
216. 
 
Marder, S., Davis, J. & Chouinard, G. (1997). The effects of risperidone on the five 
dimensions of schizophrenia derived by factor analysis: combined results of the North 
American trials. Journal of Clinical Psychiatry, 58(12), 538-546.  
 
Mattison, D., Blann, E. & Malek, A. (1991). Physiological alterations during pregnancy: 




McGivern, R., Henschel, D., Hutcheson, M. & Pangburn, T. (1996). Sex differences in daily 
water consumption of rats: effect of housing and hormones. Physiology and Behavior, 
(59), 653-658. 
 
Mead, A., Li, Ming. & Kapur, S. (2008). Clozapine and olanzapine exhibit an intrinsic 
anxiolytic property in two conditioned fear paradigms: Contrast with haloperidol and 
chlordiazepoxide. Pharmacology, Biochemistry and Behavior, 90, 554-562. 
 
Medsafe. (2017). New Zealand Datasheet. Retrieved from 
http://www.medsafe.govt.nz/profs/Datasheet/o/OlanzapineDRLAtab.pdf  
 
Meibohm, M., Beierle, I. & Derendorf, H. (2002). How important are gender differences in 
pharmacokinetics? Clinical Pharmacokinetics, 41, 329-342. 
 
Meil, W. & Schechter, M. (1997). Olanzapine attenuates the reinforcing effects of cocaine. 
European Journal of Pharmacology, 340, 17-26. 
 
Melkersson, K., Hulting, A. & Rane, A. (2001). Dose requirements and prolactin elevation of 
antipsychotics in male and female patients with schizophrenia or related psychoses. 
British Journal of Clinical Pharmacology, 51, 317-324.  
 
Meunier, G. & Fischer, R. (1985). Sex differences in ambulation and defecation in the degu 




Meziane, H., Ouagazzal, A., Aubert, L., Wietrzych, M. & Krezel, W. (2007). Estrous cycle 
effects on behavior of C57BL/6J and BALB/cByJ female mice: implications for 
phenotyping strategies. Genes, Brain, and Behavior, 6, 192-200. 
 
Mitchell, A. (2006). Two-week delay in onset of action of antidepressants: new evidence. 
British Journal of Psychiatry, 188, 105-106. 
 
Mizukami, S., Nishizuka, M. & Arai, Y. (1983). Sexual difference in nuclear volume and its 
ontogeny in the rat amygdala. Experimental Neurology, 79, 569-575.  
 
Molho, E. & Factor, S. (1999). Worsening of motor features of Parkinsonism with 
olanzapine. Movement Disorders, 14(6), 1014-1016. 
 
Monasterio, E. & McKean, A. (2011). Off-label use of atypical antipsychotic medications in 
Canterbury, New Zealand. New Zealand Medical Journal, 124(1335), 24-29. 
 
Moore, N., Tye, N., Axton, M. & Risius, F. (1992). The behavioral pharmacology of 
olanzapine, a novel “atypical” antipsychotic agent. Journal of Pharmacology and 
Experimental Therapeutics, 262(2), 545-551. 
 
Moore, N., Rees, G., Sanger, G. & Tye, N. (1994). Effects of olanzapine and other 
antipsychotic agents on responding maintained by a conflict schedule. Behavioural 




Muller, A., Tort, A., Gnoatto, J., Moreira, J., Vinade, E., Perry, M., Souza, D., Lara, D. & 
Portela, L. (2010). Metabolic and behavioural effects of chronic olanzapine treatment 
and cafeteria diet in rats. Behavioural Pharmacology, 21(7), 668-675.  
 
Muller, M., Regenbogen, B., Sachse, J., Eich, F., Hartter, S. & Hiemke, C. (2006). Gender 
aspects in the clinical treatment of schizophrenic patients with amisulpride: a 
therapeutic drug monitoring study. Pharmacopsychiatry, 39, 41-46.  
 
Ninan, I. & Kulkarni, S. (1999). Preferential inhibition of dizocilpine-induced 
hyperlocomotion by olanzapine. European Journal of Pharmacology, 368, 1-7. 
 
Nowakowska, E., Chodera, A., Kus, K. & Rybakowski, J. (1999). Some behavioral effects of 
risperidone in rats: comparison with haloperidol. European 
Neuropsychopharmacology, 9(5), 421-426.  
 
Ortega-Alvaro, A., Gibert-Rahola, J. & Mico, J. (2006). Influence of chronic treatment with 
olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial 
maze task in rats. Progress in Neuro-psychopharmacology and Biological Psychiatry, 
30, 104-111.  
 
Pahkla, R., Kask, R. & Rago, L. (2000). Differential effects of beta-carbolines and 
antidepressants on rat exploratory activity in the elevated zero maze. Pharmacology, 




Palanza, P. (2001). Animal models of anxiety and depression: how are females different? 
Neuroscience and Biobehavioural Reviews, 25, 219-233. 
 
Parkinson, A., Mudra, D., Johnson, C., Dwyer, A. & Carroll, K. (2004). The effects of 
gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in 
human liver microsomes and inducibility in cultured human hepatocytes. Toxicology 
and Applied Pharmacology, 199(3), 193-209.  
 
Parlesak, A., Billinger, M., Bode, C. & Bode, J. (2002). Gastric alcohol dehydrogenase 
activity in man: influence of gender, age, alcohol consumption and smoking in a 
Caucasian population. Alcohol and Alcoholism, 37(4), 388-393.  
 
Pollock, B. (1997). Gender differenes in psychotropic drug metabolism. 
Psychopharmacology Bulletin, 33, 235-241. 
 
Powell, J., Martindale, B., Kulp, S., Martindale, A. & Bauman, R. (1977). Taking a closer look: 
time sampling and measurement error. Journal of Applied Behavior Analysis, (10), 325-
332.  
 
Prior, T. & Baker, G. (2003). Interactions between the cytochrome P450 system and the 





Putzhammer, A., Perfahl, M., Pfeiff, L. & Hajak, G. (2005). Gait disturbances in patients 
with schizophrenia and adaptation to treadmill walking. Psychiatry & Clinical 
Neurosciences, 59(3), 303-310. 
 
Rodgers, R., Nikulina, E. & Cole, J. (1994). Dopamine D1 and D2 receptor ligands modulate 
the behaviour of mice in the elevated plus maze. Pharmacology, Biochemistry and 
Behavior, 49(4), 985-995.  
 
Rodgers, R & Shepherd, J. (1993). Influence of prior maze experience on behaviour and 
response to diazepam in the elevated plus-maze and light/dark tests of anxiety in 
mice. Psychopharmacology, 113(2), 237-242. 
 
Roerig, J., Mitchell, J., de Zwaan, M., Crosby. R., Gosnell, B., Steffen, K. & Wonderlich, S. 
(2005). A comparison of the effects of olanzapine and risperidone versus placebo on 
eating behaviors. Journal of Clinical Pharmacology, 25, 413-418.  
 
Rogoz, Z. & Skuza, G. (2011). Anxiolytic-like effects of olanzapine, risperidone and 
fluoxetine in the elevated plus maze test in rats. Pharmacological Reports, 63, 1547-
1552. 
 
Rosengarten, H. & Quartermain, D. (2002). The effect of chronic treatment with typical and 
atypical antipsychotics on working memory and jaw movements in three- and 
eighteen-month-old rats. Progress in Neuro-psychopharmacology and Biological 




Russell, K., Hagenmeyer-Houser, S. & Sanberg, P. (1987). Haloperidol-induced emotional 
defecation: a possible model for neuroleptic anxiety syndrome. Psychopharmacology 
(Berl.), 91(1), 41-49. 
 
Schneider, P., Ho, Y., Spanagel, R. & Pawlak, C. (2011). A Novel Elevated Plus-Maze 
Procedure to Avoid the One-Trial Tolerance Problem. Frontiers in Behavioural 
Neuroscience, 43(5), 1-8. 
 
Seeman, M. (2004). Gender differences in the prescribing of antipsychotic drugs. American 
Journal of Psychiatry, 161, 1324-1333.  
 
Seliger, D. (1977). Effects of age, sex and brightness of field on open field behaviors of rats. 
Perceptual and Motor Skills, 45(3), 1059-1067. 
 
Shepherd, J., Grewal, S., Fletcher, A., Bill, D. & Dourish, C. (1994). Behavioural and 
pharmacological characterisation of the elevated “zero maze” as an animal model of 
anxiety. Psychopharmacology, 116, 56-64. 
 
Siaz-Moran, S., Estanislau, C., Canete, T., Blazquez, G., Raez, A., Tobena, A. & Fernandez-
Teruel, A. (2014). Relationships of open-field behaviour with anxiety in the elevated 





Siddiqui, A. & Shah, B. (1997). Neonatal androgen manipulation differentially affects the 
development of monoamine systems in te rat cerebral cortex, amygdala, and 
hypothalamus. Brain Research. Developmental Brain Research, 98, 247-252.  
 
Simon, P., Panissaud, C. & Constentin, J. (1993). Anxiogenic-like effects induced by 
stimulation of dopamine receptors. Pharmacology, Biochemistry and Behavior, 45(3), 
685-690.  
 
Singh, Y., Jaiswal, A., Singh, M. & Chattacharya, S. (1997). Effect of prenatal haloperidol 
administration on anxiety patterns in rats. Indian Journal of Experimental Biology, 
35(12), 1284-1290.  
 
Skarsfeldt, T. Differential effect of antipsychotics on place navigation of rats in the Morris 
water maze. A comparative study between novel and reference antipsychotics. 
Psychopharmacology (Berl.), 124(1-2), 126-133.  
 
Slob, A., Huizer, T. & Van der Werff ten Bosch, J. (1986). Ontogeny of sex differences in 
open-field ambulation in the rat. Physiology & Behavior, 37(2), 313-315.  
 
Smith, S. (2010). Gender differences in antipsychotic prescribing. International Review of 
Psychiatry, 22(5), 472-484.  
 
Soldin, O., Chung, S. & Mattison, D. (2011). Sex difference in drug disposition. Journal of 




Soldin, O. & Mattison, R. (2009). Sex differences in pharmacokinetics and 
pharmacodynamics. Clinical Pharmacokinetics, 48(3), 143-157.  
 
Stahl, S. (1998). Basic psychopharmacology of antidepressants, part 1: Antidepressants have 
seven distinct mechanisms of action. Journal of Clinical Psychiatry, 59(4), 5-14.  
 
Stark, A., Jordan, S., Allers, K., Bertekap, R., Chen, R., Mistry-Kannan, T., Molski, T., 
Yocca, F., Sharp, T., Kikuchi, T. & Burris, K. (2007). Interaction of the novel 
antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-
binding and in vivo electrophysiological studies. Psychopharmacology (Berl.), 
190(3), 373-382.  
 
Stefanidis, A., Verty, A., Allen, A., Owens, N., Cowley, M. & Oldfield, B. (2009). The role 
of thermogenesis in antipsychotic drug-induced weight gain. Obesity, 17(1), 16–24. 
 
Stephen, A., Wiggins, H., Englyst, H., Cole, T., Wayman, B. & Cummings, J. (1986). The 
effect of age, sex and level of intake of dietary fibre from wheat on large-bowel 
function in thirty healthy subjects. British Journal of Nutrition, 56(2), 349-61. 
 
Sun, T., He, W., Hu, G. & Li, M. (2010). Anxiolytic-like property of risperidone and 
olanzapine as examined in multiple measures of fear in rats. Pharmacology, 
Biochemistry and Behavior, 95, 298-307. 
 
Tamminga, W., Wemer, J, Oosterhuis, B., Weiling, J., Wilffert, B., Leij, F., de Zeeuwl, A. & 
Jonkman, J. (1999). CYP2D6 and CYP2C19 activity in a large population of Dutch 
88 
 
healthy volunteers: indications for oral contraceptive-related gender differences. 
European Journal of Clinical Pharmacology, 55(3), 177-184.  
 
Tanaka, K., Shimizu, N., Imura, H., et al. (1993). Human corticotropin-releasing hormone 
(hCRH) test: sex and age differences in plasma ACTH and cortisol responses and 
their reproducibility in healthy adults. Endocrine Journal, 40(5), 571-9. 
 
Terry, A., Hill, W., Parikh, V., Evans, D., Waller, J. & Mahadik, S. (2002). Differential 
effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers 
and spatial learning in rats. Psychopharmacology, 164, 360-368. 
 
Thurmann, P & Hompesch, B. (1998). Influence of gender on the pharmacokinetics and 
pharmacodynamics of drugs. International Journal of Clinical Pharmacology and 
Therapeutics, 36, 586-590.  
 
Tran, P., Dellva, M., Tollefson, G., Beasley, C., Potvin, J. & Kessler, G. (1997). 
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the 
acute treatment of schizophrenia. Journal of Clinical Psychiatry, 58(5), 205-211. 
 
US General Accounting Office (GAO). (2001). Drug safety: most drugs withdrawn in recent 





van der Zwaal., E., Luijendijk, M., Evers, S., la Fleur, S. & Adan, R. (2010). Olanzapine 
affects locomotor activity and meal size in male rats. Pharmacology, Biochemistry 
and Bheavior, 97, 130-137. 
 
van der Zwaal, E., Merkestein, M., Lam, Y., Brans, M., Luijendijk, M., Bok, L., Verheij, E. 
la Fleur, S. & Adan, R. (2012). The acute effects of olanzapine on ghrelin secretion, 
CCK sensitivity, meal size, locomotor activity and body temperature. International 
Journal of Obesity, 36, 254-261. 
 
Vierhapper, H., Nowotny, P. & Waldhausl, W. (1998). Sex-specific differences in cortisol 
production rates in humans. Metabolism, 47(8), 974-6. 
 
Walsh, R. & Cummins, R. (1976). The open field test: a critical review. Psychological 
Bulletin, 83(3), 482-504. 
 
Weiss, U., Marksteiner, J., Kemmler, G., Saria, A. & Aichhorn, W. (2005). Effects of age and 
sex on olanzapine plasma concentrations. Journal of Clinical Psychopharmacology, 
25 (570-574).  
 
Weston-Green, K., Huang, X. & Deng, C. (2011). Sensitivity of the female rat to olanzapine-
induced weight gain – far from the clinic? Schizophrenia Research, 116, 299-300. 
 
Wheeler, A. (2006). Atypical antipsychotic use for adult outpatients in New Zealand’s 




Wolff, M. & Leander, J. (2003). Comparison of the effects of antipsychotics on a delayed 
radial maze task in the rat. Psychopharmacology (Berl.), 168(4), 410-416. 
 
World Health Organisation. (1998). Nations for Mental Health: Schizophrenia and public 
health. Retrieved from http://www.who.int/mental_health/media/en/55.pdf  
 
Zhang, L., Ma, W., Barker, J. & Rubinow, D. (1999). Sex differences in expression of 
serotonin receptors (subtypes 1A and 2A) in rat’s brain: a possible role of 
testosterone. Neuroscience, 94, 251-259. 
 
Zhang, Q., Lian, J., He, M., Deng, C., Wang, H. & Huang, X. (2014). Olanzapine reduced 
brown adipose tissue thermogenesis and locomotor activity in female rats. Progress in 




6 Appendix A 
 
 
 
 
 
 
 
 
 
 
 
 
 
